Probiotics for patients with hepatic encephalopathy by McGee, Richard G et al.
Cochrane
Library
 
Cochrane Database of Systematic Reviews
  Probiotics for patients with hepatic encephalopathy (Review)  
  McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC  
  McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. 
Probiotics for patients with hepatic encephalopathy. 
Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD008716. 
DOI: 10.1002/14651858.CD008716.pub2.
 
  www.cochranelibrary.com  
Probiotics for patients with hepatic encephalopathy (Review) 
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
T A B L E   O F   C O N T E N T S
HEADER......................................................................................................................................................................................................... 1
ABSTRACT..................................................................................................................................................................................................... 1
PLAIN LANGUAGE SUMMARY....................................................................................................................................................................... 2
SUMMARY OF FINDINGS.............................................................................................................................................................................. 3
BACKGROUND.............................................................................................................................................................................................. 8
OBJECTIVES.................................................................................................................................................................................................. 8
METHODS..................................................................................................................................................................................................... 8
RESULTS........................................................................................................................................................................................................ 11
Figure 1.................................................................................................................................................................................................. 12
Figure 2.................................................................................................................................................................................................. 16
Figure 3.................................................................................................................................................................................................. 17
DISCUSSION.................................................................................................................................................................................................. 19
AUTHORS' CONCLUSIONS........................................................................................................................................................................... 19
ACKNOWLEDGEMENTS................................................................................................................................................................................ 19
REFERENCES................................................................................................................................................................................................ 20
CHARACTERISTICS OF STUDIES.................................................................................................................................................................. 31
DATA AND ANALYSES.................................................................................................................................................................................... 48
Analysis 1.1. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 1 All cause mortality......................................... 51
Analysis 1.2. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 2 No recovery (incomplete resolution of clinical
symptoms).............................................................................................................................................................................................
52
Analysis 1.3. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 3 Number of adverse events............................ 52
Analysis 1.4. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 4 Quality of life SF-36 physical/ mental........... 53
Analysis 1.5. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 5 Change of/or withdrawal from treatment...... 53
Analysis 1.6. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 6 Plasma ammonia concentration (μmol/L)...... 54
Analysis 1.7. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 7 Change in plasma ammonia concentration
(μmol/L).................................................................................................................................................................................................
54
Analysis 1.8. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 8 No recovery (subgroup type of probiotic
used).......................................................................................................................................................................................................
55
Analysis 1.9. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 9 No recovery (subgroup grade of hepatic
encephalopathy)...................................................................................................................................................................................
55
Analysis 1.10. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 10 No recovery (subgroup duration of
therapy)..................................................................................................................................................................................................
56
Analysis 1.11. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 11 No recovery (subgroup co-interventions
used).......................................................................................................................................................................................................
56
Analysis 1.12. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 12 Plasma ammonia concentration (subgroup
type of probiotic used).........................................................................................................................................................................
57
Analysis 1.13. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 13 Plasma ammonia concentration (subgroup
grade of hepatic encephalopathy).......................................................................................................................................................
58
Analysis 1.14. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 14 Plasma ammonia concentration (subgroup
duration of therapy)..............................................................................................................................................................................
58
Analysis 1.15. Comparison 1 Probiotic versus placebo/ no intervention, Outcome 15 Plasma ammonia concentration (subgroup
co-interventions used)..........................................................................................................................................................................
59
Analysis 2.1. Comparison 2 Probiotic versus lactulose, Outcome 1 No recovery (incomplete resolution of clinical symptoms)...... 60
Analysis 2.2. Comparison 2 Probiotic versus lactulose, Outcome 2 Number of adverse events...................................................... 61
Analysis 2.3. Comparison 2 Probiotic versus lactulose, Outcome 3 Change of/or withdrawal from treatment.............................. 61
Analysis 2.4. Comparison 2 Probiotic versus lactulose, Outcome 4 Plasma ammonia concentration (μmol/L)............................. 62
Analysis 2.5. Comparison 2 Probiotic versus lactulose, Outcome 5 Change in plasma ammonia concentration (μmol/L)............ 62
Analysis 2.6. Comparison 2 Probiotic versus lactulose, Outcome 6 Plasma ammonia concentration (subgroup type of probiotic
used).......................................................................................................................................................................................................
63
Analysis 2.7. Comparison 2 Probiotic versus lactulose, Outcome 7 Plasma ammonia concentration (subgroup grade of hepatic
encephalopathy)...................................................................................................................................................................................
63
ADDITIONAL TABLES.................................................................................................................................................................................... 63
APPENDICES................................................................................................................................................................................................. 64
Probiotics for patients with hepatic encephalopathy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
i
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
CONTRIBUTIONS OF AUTHORS................................................................................................................................................................... 65
DECLARATIONS OF INTEREST..................................................................................................................................................................... 65
SOURCES OF SUPPORT............................................................................................................................................................................... 66
DIFFERENCES BETWEEN PROTOCOL AND REVIEW.................................................................................................................................... 66
INDEX TERMS............................................................................................................................................................................................... 66
Probiotics for patients with hepatic encephalopathy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ii
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
[Intervention Review]
Probiotics for patients with hepatic encephalopathy
Richard G McGee1, Anouk Bakens2, Kerrie Wiley3, Stephen M Riordan4, Angela C Webster1
1Sydney School of Public Health, University of Sydney, Sydney, Australia. 2Department of medicine, Nijmegen, Netherlands. 3Discipline
of Paediatrics and Child Health, University of Sydney, Sydney, Australia. 4Gastrointestinal and Liver Unit, The Prince of Wales, Randwick,
Australia
Contact address: Richard G McGee, Sydney School of Public Health, University of Sydney, Sydney, NSW, 2006, Australia.
dr.richardmcgee@gmail.com, dr.richardmcgee@gmail.com.
Editorial group: Cochrane Hepato-Biliary Group
Publication status and date: New, published in Issue 11, 2011.
Citation: McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane
Database of Systematic Reviews 2011, Issue 11. Art. No.: CD008716. DOI: 10.1002/14651858.CD008716.pub2.
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Hepatic encephalopathy is a disorder of brain function as a result of liver failure and/or portosystemic shunt. Both hepatic encephalopathy
(clinically overt) and minimal hepatic encephalopathy (not clinically overt) significantly impair patient’s quality of life and daily functioning
and represent a significant burden on health care resources. Probiotics are live microorganisms, which when administered in adequate
amounts may confer a health benefit on the host.
Objectives
To quantify the beneficial and harmful eKects of any probiotic in any dosage, compared with placebo or no intervention, or with any other
treatment for patients with any grade of acute or chronic hepatic encephalopathy as assessed from randomised trials.
Search methods
We searched the The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL)
in The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Expanded, conference proceedings, reference lists of included trials and
the WHO international clinical trials registry until April 2011 registry platform to identify new and ongoing trials.
Selection criteria
We included randomised trials that compared probiotics in any dosage with placebo or no intervention, or with any other treatment in
patients with hepatic encephalopathy.
Data collection and analysis
Three authors independently assessed the risk of bias of the included trials and extracted data on relevant outcomes, with diKerences
resolved by consensus. We conducted random-eKects model meta-analysis due to obvious heterogeneity of patients and interventions.
A P value of 0.05 or less was defined as significant. Dichotomous outcomes are expressed as risk ratio (RR) and continuous outcomes as
mean diKerence (MD) with 95% confidence intervals (CI).
Main results
We included seven trials of which 550 participants were randomised. Four of the seven trials compared a probiotic with placebo or no
treatment in 245 participants, another trial compared a probiotic with lactulose in 40 participants , and the remaining two trials compared
a probiotic with both placebo and lactulose in 265 participants. Each trial used diKerent types of probiotics. Duration of administration
of the experimental intervention varied from 10 days to 180 days. Two trials were industry funded, and five were unclear about origin of
funding. All trials had high risk of bias.
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When probiotics were compared with no treatment, there was no significant diKerence in all-cause mortality (2 trials, 105 participants;
1/57 (2%) versus 1/48 (2%): RR 0.72; 95% CI 0.08 to 6.60), lack of recovery (4 trials, 206 participants; 54/107 (50%) versus 68/99 (69%): RR
0.72; 95% CI 0.49 to 1.05), adverse events (3 trials, 145 participants; 2/77 (3%) versus 6/68 (9%): RR 0.34; 95% CI 0.08 to 1.42), quality of
life (1 trial, 20 participants contributed to the physical quality of life measurement, 20 participants contributed to the mental quality of
life: MD Physical 0.00; 95% CI -5.47 to 5.47; MD Mental 4.00; 95% CI -1.82 to 9.82), or change of/or withdrawal from treatment (3 trials, 175
participants; 11/92 (12%) versus 7/83 (8%): RR 1.28; 95% CI 0.52 to 3.19). No trial reported sepsis or duration of hospital stay as an outcome.
Plasma ammonia concentration was significantly lower for participants treated with probiotic at one month (3 trials, 226 participants: MD
-2.99 μmol/L; 95% CI -5.70 to -0.29) but not at two months (3 trials, 181 participants: MD -1.82 μmol/L; 95% CI -14.04 to 10.41). Plasma
ammonia decreased the most in the participants treated with probiotic at three months (1 trial, 73 participants: MD -6.79 μmol/L; 95% CI
-10.39 to -3.19).
When probiotics were compared with lactulose no trial reported all-cause mortality, quality of life, duration of hospital stay, or septicaemia.
There were no significant diKerences in lack of recovery (3 trials, 173 participants; 47/87 (54%) versus 44/86 (51%): RR 1.05; 95% CI 0.75 to
1.47), adverse events (2 trials, 111 participants; 3/56 (5%) versus 6/55 (11%): RR 0.57; 95% CI 0.06 to 5.74), change of/or withdrawal from
treatment at one month (3 trials, 190 participants; 8/95 (8%) versus 7/95 (7%): RR 1.10; 95% CI 0.40 to 3.03), plasma ammonia concentration
(2 trials, 93 participants: MD -6.61 μmol/L; 95% CI -30.05 to 16.84), or change in plasma ammonia concentration (1 trial, 77 participants:
MD 1.16 μmol/L; 95% CI -1.96 to 4.28).
Authors' conclusions
The trials we located suKered from a high risk of systematic errors ('bias') and high risk of random errors ('play of chance'). While probiotics
appear to reduce plasma ammonia concentration when compared with placebo or no intervention, we are unable to conclude that
probiotics are eKicacious in altering clinically relevant outcomes. Demonstration of unequivocal eKicacy is needed before probiotics can
be endorsed as eKective therapy for hepatic encephalopathy. Further randomised clinical trials are needed.
P L A I N   L A N G U A G E   S U M M A R Y
Probiotics for patients with hepatic encephalopathy
Hepatic encephalopathy is a disorder of the brain function as a result of liver failure and/or portosystemic shunt. It results in confusion,
drowsiness, coma, and in some patients, in death. While the cause of hepatic encephalopathy is not fully understood, it is thought to
develop as a result of the failure to clear various toxic substances, such as ammonia, from the blood, either because of poor function of the
liver cells or because the blood from the intestine is shunted around the liver and is not seen by the liver cells. Protein metabolising bacterial
species in the intestine of hepatic encephalopathy patients contribute to ammonia production. Probiotics are live microorganisms who
may reduce the prevalence of these harmful ammonia-producing bacteria. This review identified seven trials of which 550 participants
were randomised. Each trial used diKerent types of probiotics. Duration of administration of the experimental intervention varied from 10
days to 180 days. The authors of the review assessed a range of outcomes including death, recovery, adverse events, and quality of life.
There was no benefit of probiotics shown for any of the primary outcomes including mortality. The authors of the review found a significant
diKerence in plasma ammonia concentration aOer one month, and a significant change in plasma ammonia concentration at three months
treatment compared with no treatment. However, this finding is of questionable importance. Therefore, the use of probiotics for patients
with hepatic encephalopathy cannot be currently recommended. Furtehr randomised clinical trials are required.
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Summary of findings for the main comparison.   Probiotic versus placebo/ no intervention for patients with hepatic encephalopathy
Probiotic versus placebo/ no intervention for patients with hepatic encephalopathy
Patient or population: patients with patients with hepatic encephalopathy. 
Settings: inpatients. 
Intervention: probiotic versus placebo/ no intervention.
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Probiotic versus placebo/ no in-
tervention
Relative ef-
fect 
(95% CI)
No of Partici-
pants 
(studies)
Quality of the
evidence 
(GRADE)
Comments
Study population
21 per 1000 21 per 1000 
(2 to 189)
Low
0 per 1000 0 per 1000 
(0 to 0)
High
All cause mortality 
Follow-up: 2 to 3 months
25 per 1000 25 per 1000 
(3 to 227)
RR 0.72 
(0.08 to 6.60)
105 
(2 studies)
⊕⊝⊝⊝ 
very low1,2,3
 
Study population
687 per 1000 488 per 1000 
(323 to 742)
Low
500 per 1000 355 per 1000 
(235 to 540)
No recovery (incomplete resolution of
clinical symptoms) 
Follow-up: 1 to 3 months
High
RR 0.72 
(0.49 to 1.05)
206 
(4 studies)
⊕⊕⊝⊝ 
low1,3
 
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
Probiotics for patients w
ith hepatic encephalopathy (Review
)
Copyright ©
 2011 The Cochrane Collaboration. Published by John W
iley & Sons, Ltd.
4
900 per 1000 639 per 1000 
(423 to 972)
Study population
88 per 1000 26 per 1000 
(4 to 141)
Low
0 per 1000 0 per 1000 
(0 to 0)
High
Number of adverse events 
Follow-up: 1 to 3 months
250 per 1000 72 per 1000 
(13 to 400)
RR 0.34 
(0.08 to 1.42)
145 
(3 studies)
⊕⊕⊝⊝ 
low1,3
 
Quality of life SF-36 physical/ mental 
Follow-up: median 2 months
See comment See comment Not estimable 40 
(1 study)
⊕⊕⊝⊝ 
low1,3
The results of
a single study
cannot be
pooled.
Study population
84 per 1000 121 per 1000 
(47 to 308)
Low
0 per 1000 0 per 1000 
(0 to 0)
High
Change of/or withdrawal from treat-
ment 
Follow-up: 1 to 3 months
110 per 1000 157 per 1000 
(62 to 402)
RR 1.28 
(0.52 to 3.19)
175 
(3 studies)
⊕⊕⊝⊝ 
low1,3
 
Plasma ammonia concentration
(µmol/L) 
Follow-up: 1 to 2 months
  The mean plasma ammonia con-
centration (µmol/l) in the inter-
vention groups was 
2.99 lower 
(5.7 to 0.29 lower)
  226 
(3 studies)
⊕⊝⊝⊝ 
very low1,2,4
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Change in plasma ammonia concen-
tration (µmol/L)
See comment See comment Not estimable 73 
(1)
See comment The results of
a single study
cannot be
pooled.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate.
1 Studies judged as high risk of bias.
2 Inconsistent interventions.
3 Wide confidence intervals.
4 Surrogate marker for clinically important outcomes.
 
 
Summary of findings 2.   Probiotic versus lactulose for hepatic encephalopathy
Probiotic versus lactulose for hepatic encephalopathy
Patient or population: patients with hepatic encephalopathy. 
Settings: inpatients. 
Intervention: probiotic versus lactulose.
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Probiotic versus lactulose
Relative ef-
fect 
(95% CI)
No of Partici-
pants 
(studies)
Quality of the
evidence 
(GRADE)
Comments
Study population
512 per 1000 532 per 1000 
(373 to 747)
Low
No recovery (incomplete resolution of
clinical symptoms) 
Follow-up: median 1 months
450 per 1000 468 per 1000 
RR 1.05 
(0.75 to 1.47)
173 
(3 studies)
⊕⊕⊝⊝ 
low1,2
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(329 to 657)
High
600 per 1000 624 per 1000 
(438 to 876)
Study population
109 per 1000 56 per 1000 
(5 to 559)
Low
100 per 1000 51 per 1000 
(5 to 512)
High
Number of adverse events 
Follow-up: mean 1 months
250 per 1000 128 per 1000 
(13 to 1000)
RR 0.57 
(0.06 to 5.74)
111 
(2 studies)
⊕⊕⊝⊝ 
low1,3
 
Study population
74 per 1000 71 per 1000 
(25 to 203)
Low
90 per 1000 86 per 1000 
(31 to 248)
High
Change of/or withdrawal from treat-
ment 
Follow-up: median 1 months
110 per 1000 106 per 1000 
(37 to 302)
RR 1.10 
(0.40 to 3.03)
190 
(3 studies)
⊕⊕⊝⊝ 
low1,3
 
Plasma ammonia concentration
(µmol/L) 
Follow-up: median 1 months
  The mean plasma ammonia con-
centration (µmol/l) in the interven-
tion groups was 
6.61 lower 
(30.05 lower to 16.84 higher)
  93 
(2 studies)
⊕⊝⊝⊝ 
very
low1,2,3,4
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Change in plasma ammonia concen-
tration (µmol/L) 
Follow-up: mean 3 months
  The mean change in plasma am-
monia concentration (µmol/l) in
the intervention groups was 
1.16 higher 
(1.96 lower to 4.28 higher)
  77 
(1 study)
⊕⊝⊝⊝ 
very low1,3,4
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence 
High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Very low quality: We are very uncertain about the estimate.
1 Studies judged as high risk of bias.
2 Inconsistent interventions.
3 Wide confidence intervals.
4 Surrogate marker for clinically important outcomes.
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B A C K G R O U N D
Description of the condition
Hepatic encephalopathy (also known as portosystemic
encephalopathy) is a reversible neuropsychiatric disorder seen in
the context of either acute or chronic liver failure or portosystemic
shunting, or both (Ferenci 2002). Hepatic encephalopathy
is characterised by complex cognitive dysfunction, which is
independent of sleep dysfunction or problems with overall
intelligence (Blei 2001). Minimal hepatic encephalopathy (MHE)
is a milder form of the same condition, which does not have
obvious clinical signs (Stewart 2007; Bajaj 2011). The onset of
hepatic encephalopathy indicates a poor prognostic outcome. It
may also reduce quality of life and level of daily functioning
(Groeneweg 1998; Arguedas 2003). The pathophysiology of hepatic
encephalopathy is still uncertain, but the prevailing assumption
is that diKerent toxins, such as false neurotransmitters, natural
benzodiazepines, short chain fatty acids, and mercaptans enhance
the negative eKects of ammonia on the level of consciousness
(Butterworth 1987; Blei 2001; Vaquero 2003). Current therapeutic
options include intensive supportive care, identification and
correction of the precipitating causes, tailored dietary restrictions,
non-absorbable disaccharides, L-ornithine L-aspartate, and/or oral
antibiotics (Riordan 1997; Blei 2001; Als-Nielsen 2003; Als-Nielsen
2004a; Als-Nielsen 2004b; Als-Nielsen 2004c; Jiang 2009).
Description of the intervention
Probiotics are live microorganisms, which when administered
in adequate amounts may confer a health benefit on the host
(Schrezenmeir 2001). However, the dose needed to confer a health
benefit is unknown for many conditions. Probiotics commonly
come from two groups of bacteria, Lactobacillus or Bifidobacterium.
Within each group, there are diKerent species (for example,
Lactobacillus acidophilus and Bifidobacterium bifidus), and within
each species, diKerent strains (or varieties). A few common
probiotics, such as Saccharomyces boulardii, are yeasts, which are
diKerent from bacteria. Therapeutic eKects may be strain specific,
and so caution must be exerted in generalising results from one
species to another. While probiotics are generally considered safe,
adverse events have been attributed to their use (Besselink 2008).
How the intervention might work
There is some evidence for an alteration in the composition of the
gastrointestinal bacterial flora of patients with liver disease (Rolfe
2000). Amongst other potential reasons, one rationale behind
the use of probiotics for hepatic encephalopathy is to reduce
the prevalence of harmful ammonia-producing bacteria in the
gastrointestinal system.
Why it is important to do this review
Hepatic encephalopathy significantly impairs patient’s quality
of life and daily functioning (Groeneweg 1998; Arguedas 2003).
Caring for and treating patients with hepatic encephalopathy is
a significant burden on the health care system. In 2003 hepatic
encephalopathy cost the US health-care system an estimated $932
million (Poordad 2007). Previous Cochrane Hepato-Biliary Group
systematic reviews have only shown moderate, and in some cases,
no benefit for current therapies for hepatic encephalopathy, which
include non-absorbable disaccharides and oral antibiotics (Als-
Nielsen 2003; Als-Nielsen 2004a; Als-Nielsen 2004b; Als-Nielsen
2004c).
O B J E C T I V E S
To determine the beneficial and harmful eKects associated with
the use of probiotics in any dosage, compared with placebo or no
intervention or with any other treatment for patients with any grade
of acute or chronic hepatic encephalopathy. This review does not
consider the primary prophylaxis of hepatic encephalopathy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised trials that compared probiotics with
placebo or no intervention, or with any other treatment for patients
with hepatic encephalopathy. We did not apply any restrictions on
language of publication, publication date, or publication status. We
excluded quasi-randomised trials.
Types of participants
Inclusion criteria
We included all patients with any grade of acute or chronic hepatic
encephalopathy in connection with acute and chronic liver disease
as well as acute hepatic failure, no matter the aetiology of liver
disease or factors precipitating the hepatic encephalopathy.
Exclusion criteria
We excluded trials with patients in whom a diagnosis of hepatic
encephalopathy was not confirmed, ie, where altered mental
status or cognitive function was not confirmed by a standardised
neuropsychological assessment. Where co-interventions such as
medication was being administered, they had to be administered
equally across the relevant intervention groups of the trial, so that
fair comparisons could be made.
Types of interventions
Any probiotic at any dose for any duration. Additional co-
interventions were allowed if received by all trial intervention
groups and were deemed suKiciently similar across trial groups.
Where synbiotics were used (a combination of a prebiotic and a
probiotic), the control group must have received a similar prebiotic
to be included in the review; such that across trial groups, the
diKerence in intervention(s) was probiotic alone. For example,
probiotic and lactulose versus antibiotic plus lactulose. Here the
comparison would have been probiotics versus antibiotic. If a trial
compared probiotics and prebiotics versus prebiotics, the trial
would have been considered a probiotic versus placebo trial, as
the diKerence between the two groups would have been probiotic
alone. A prebiotic is a substance that stimulates the growth of
probiotics.
Types of outcome measures
All outcomes were assessed at time points reported by authors, but,
where possible, also summarised at one, two, three, six months,
and one year.
Primary outcomes
1. All-cause mortality: number of participants dead.
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2. Number of participants who did not recover from hepatic
encephalopathy (defined as incomplete resolution of clinical
symptoms).
3. Adverse events: number and type of adverse events
defined as patients with any untoward medical occurrence.
We summarised adverse events that lead to treatment
discontinuation and those that did not lead to treatment
discontinuation separately. Serious adverse events were
defined according to the International Conference on
Harmonisation (ICH) Guidelines (ICH-GCP 1997) as any event
that led to death, was life-threatening, required in-patient
hospitalisation or prolongation of existing hospitalisation,
resulted in persistent or significant disability, and any important
medical event, which may have jeopardised the patient or
required intervention to prevent it. All other adverse events were
considered non-serious.
4. Quality of life: as measured by the SF-36 scale or other similar
validated scales (Brazier 1992; Ware 1994).
Secondary outcomes
1. Change of or withdrawal from treatment: number of participants
who changed/withdrew from their allocated treatment regimen.
2. Sepsis: the number of participants with one or more episodes of
sepsis (confirmed by a positive blood culture).
3. Change in plasma ammonia concentration.
4. Duration of stay in hospital: measured in days.
Search methods for identification of studies
Electronic searches
We searched The Cochrane Hepato-Biliary Group Controlled
Trials Register, the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library, MEDLINE (Ovid SP), EMBASE
(Ovid SP), and Science Citation Index Expanded (Web of Science)
(Royle 2003). The search strategies with the time span of the
searches are given in Appendix 1. The search filter for randomised
trials in MEDLINE (via Ovid SP) was created by Lefebvre 2011, and
the search filter for randomised trials in EMBASE (via Ovid SP) was
created by Sharon 2006.
We also searched the World Health Organisation (WHO)
international clinical trials registry platform for ongoing and
unpublished trials (October 2010) (http://apps.who.int/trialsearch/
AdvSearch.aspx) using an advanced search for the condition
'hepatic encephalopathy' and intervention 'probiotic'.
Searching other resources
We hand-searched the proceedings of three relevant conferences:
1. The American Association for the Study of Liver Disease (AASLD)
from 2005 to 2009.
2. The European Association for the Study of the Liver (EASL) from
2005 to 2010.
3. Digestive Diseases Week (DDW) from 2005 to 2010, using
the following keywords: 'hepatic encephalopathy', 'probiotic',
'bifidobacterium', 'lactobacillus', and 'liver disease'.
We identified further trials through reference lists of relevant
articles and by contacting content experts and authors of included
trials. We applied no date or language restrictions. We translated
non-English language articles using Google translate (http://
translate.google.com.au/).
Data collection and analysis
Selection of studies
Three authors, working independently of one another, conducted
trial selection and data extraction. None of them was blinded
to journal or author names. Authors resolved disagreements by
consensus.
Data extraction and management
We extracted the following information using a standardised data
extraction form:
• General information: author(s), title, source, contact address,
year of trial, country of trial, language of publication, year of
publication.
• Trial characteristics: design (randomised clinical trial),
randomisation method, manner of recruitment, sampling method,
duration of intervention period, length of follow up, reason for and
number of dropouts and withdrawals, adverse events.
• Patients: baseline characteristics of participants in treatment
groups such as sex, age, prevalence of co-morbidities (eg, diabetes),
inclusion and exclusion trial criteria.
• Trial setting: eg, in-patient/out-patient department, emergency
department.
• Detailed description of both the intervention and the comparison
intervention, type, dose, and duration of probiotic(s).
• Outcomes: specific outcome reported, assessment instrument
used, scoring range where appropriate.
• Any co-interventions.
We entered data into Review Manager 5 soOware (RevMan 2011)
and checked the data for accuracy.
Assessment of risk of bias in included studies
Methodological quality was defined as the confidence that the
design and the report of the randomised clinical trial would restrict
bias in the comparison of the intervention (Moher 1998). According
to empirical evidence (Schulz 1995; Moher 1998; Kjaergard 2001;
Wood 2008), the methodological quality of the trials, hence risk of
bias, was based on the following domains:
Sequence generation
• Low risk of bias: the methods used was either adequate
eg, computer-generated random numbers, table of random
numbers or unlikely to introduce bias.• Uncertain risk of bias: there was insuKicient information to
assess whether the method used was likely to introduce
confounding.• High risk of bias: the method used was not best practise for
randomisation.
Allocation concealment
• Low risk of bias: the method used (eg, central allocation) was
unlikely to induce bias on the final observed eKect.• Uncertain risk of bias: there was insuKicient information to
assess whether the method used was likely to induce bias on the
estimate of eKect.• High risk of bias: the method used (eg, open random allocation
schedule) was likely to induce bias on the final observed eKect.
Probiotics for patients with hepatic encephalopathy (Review)
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Blinding of participants
• Low risk of bias: blinding was performed adequately, or the
outcome was not likely to be influenced by lack of blinding.• Uncertain risk of bias: there was insuKicient information to
assess whether the type of blinding used was likely to induce
bias on the eKect.• High risk of bias: no blinding or incomplete blinding, and the
outcome was likely to be influenced by lack of blinding.
Blinding of personnel
• Low risk of bias: blinding was performed adequately, or the
outcome was not likely to be influenced by lack of blinding.• Uncertain risk of bias: there was insuKicient information to
assess whether the type of blinding used was likely to induce
bias on the eKect.• High risk of bias: no blinding or incomplete blinding, and the
outcome was likely to be influenced by lack of blinding.
Blinding of outcome assessors
• Low risk of bias: blinding was performed adequately, or the
outcome measurement was not likely to be influenced by lack of
blinding.• Uncertain risk of bias: there was insuKicient information to
assess whether the type of blinding used was likely to induce
bias on the estimate of eKect.• High risk of bias: no blinding or incomplete blinding, and the
outcome measurement was likely to be influenced by lack of
blinding.
Incomplete outcome data
• Low risk of bias: the underlying reasons for missing data were
unlikely to make treatment eKects depart from plausible values,
or appropriate methods have been employed to handle missing
data.• Uncertain risk of bias: there was insuKicient information to
assess whether the missing data mechanism in combination
with the method used to handle missing data was likely to
induce bias on the estimate of eKect.• High risk of bias: the crude estimate of eKects (eg, complete case
estimate) were clearly biased due to the underlying reasons for
missing data, and the methods used to handle missing data were
unsatisfactory.
Selective outcome reporting
• Low risk of bias: the trial protocol was available or the
study author provided further information about pre-specified
outcomes and all of the trial's pre-specified outcomes that were
of interest in the review were reported or similar.• Uncertain risk of bias: there was insuKicient information to
assess whether the magnitude and direction of the observed
eKect were related to selective outcome reporting.• High risk of bias: not all of the trial's pre-specified primary
outcomes were reported or similar.
Other bias
• Low risk of bias: the trial was independently funded, eg, by a
government organisation or university.• Uncertain risk of bias: the trial did not declare its funding source.• High risk of bias: the trial was industry funded, eg, by a
pharmaceutical company or an author was an employee of a
pharmaceutical company.
Trials judged as having  'low risk of bias' in  all of the  specified
individual domains were considered 'trials with low risk of bias'.
Trials judged as having 'uncertain risk of bias' or 'high risk of
bias'  in one or more of the specified individual domains  were
considered  'trials with high risk of bias'. Authors of the original
reports were contacted to provide further details when any of the
above information was unclear.
Measures of treatment e;ect
We conducted data analysis according to the guidelines presented
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011) and The Cochrane Hepato-Biliary Group Module
(Gluud 2011).
Dichotomous data: we presented results as summary risk ratio (RR)
with 95% confidence intervals (CI).
Continuous data: we presented results as mean diKerence (MD) if
outcomes were measured in the same way amongst trials.
Dealing with missing data
Data for all participants were analysed in the group to which
they are allocated, regardless of whether or not they received the
allocated intervention. If in the original reports, participants were
not analysed in the group to which they were randomised and
there was suKicient information in the trial report, we attempted to
restore them to the correct group, ie, intention-to-treat analysis was
conducted where it was possible to do so. Where data were missing,
we sought clarification from the authors of the trial. If intention-
to-treat analysis was not possible, we conducted available case
analysis or per protocol analysis.
Assessment of heterogeneity
We assessed heterogeneity amongst trials, when appropriate, using
the I2 and Cochran Q statistics. Where substantial heterogeneity
was detected (I2 more than 50% or P less than 0.10), we explored it
by pre-specified subgroup analysis and sensitivity analysis.
Assessment of reporting biases
Where reporting bias was suspected (see selective reporting
bias above), we made an attempt to contact trial authors to
provide missing outcome data. When missing data were thought
to potentially introduce serious bias, the impact of including such
trials in the overall assessment of results was explored by a
sensitivity analysis. Funnel plot asymmetry was used to assess the
existence of bias where there were at least ten trials.
Data synthesis
We conducted statistical analysis with random-eKects model meta-
analyses using the Review Manager 5 soOware (RevMan 2011).
Random-eKects models were used for all analyses where trials
examined the same intervention, and the trials populations and
methods were judged suKiciently similar. We originally planned to
conduct also fixed-eKect model meta-analysis, but abstained due
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to obvious heterogeneity of patients and intervention. A P value of
0.05 or less was defined as significant.
Subgroup analysis and investigation of heterogeneity
Priori subgroup analyses were:
- Type of probiotic (by genus): Lactobacillus, Bifidobacteria, mixed,
or unclear.
- Grade of hepatic encephalopathy: minimal compared to overt.
- Duration of therapy.
- MELD (model for end-stage liver disease) score.
- Co-interventions used.
- Trials with low risk of bias compared to trials with high risk of bias.
We assessed diKerences among subgroups by test of interaction
(Altman 1996).
Sensitivity analysis
We carried out sensitivity analysis when significant heterogeneity
was detected (I2 more than 50% or P less than 0.10) to determine
the source, that is trials were sequentially removed from the
analysis to determine which trial or trials were contributing to the
heterogeneity.
R E S U L T S
Description of studies
Results of the search
The process of identifying randomised clinical trials for inclusion in
the review is outlined in Figure 1.
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Figure 1.   Study flow diagram.
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Figure 1.   (Continued)
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Figure 1.   (Continued)
 
The electronic searches of The Cochrane Hepato-Biliary Group
Controlled Trials Register (n = 9), the Cochrane Central Register
of Controlled Trials (n = 21), MEDLINE (n = 37), EMBASE (n =
138), and Science Citation Index Expanded (n = 70) identified a
total of 275 publications. Two additional trials were identified
from reference lists and trial registry searching. Hand searching of
conference proceedings, contacting content experts and authors
produced no extra trials. AOer excluding duplicates, 197 unique
records remained. Of these 172 were excluded aOer reviewing
titles and abstracts and of the remaining 25 publications, which
were assessed aOer reviewing their full texts, a further 18 trials
were excluded. Therefore, a total of seven trials reported in nine
publications were included in the review.
One of these seven trials (Mittal 2009) was available as an abstract,
whilst the remaining six trials were published in four diKerent
journals. One ongoing trial (Sharma 2010) was identified; therefore,
the results were not available for use in the review. However,
information about the trial is provided in the characteristics of
ongoing studies table (Characteristics of ongoing studies).
Included studies
Of the seven included trials, four trials compared a probiotic with
placebo or no treatment in 245 participants (Liu 2004; Bajaj 2008;
Malaguarnera 2010; Pereg 2011). One trial compared a probiotic
with lactulose in 40 participants (Loguercio 1987). Two trials
compared a probiotic both with placebo and with lactulose in 265
participants (Mittal 2009; Sharma 2008). Each trial used diKerent
probiotics see Table 1.
Five trials enrolled participants with minimal hepatic
encephalopathy (Liu 2004; Bajaj 2008; Sharma 2008; Mittal 2009;
Pereg 2011) and two trials enrolled participants with overt hepatic
encephalopathy (grade I or II according to the West-Haven criteria)
(Loguercio 1987; Malaguarnera 2010).
Excluded studies
A total of 190 records were excluded.
Risk of bias in included studies
Reporting of trial methodology was incomplete for the majority of
the domains as summarised in Figure 2 and Figure 3. Therefore, we
classified all trials as having a high risk of bias.
 
Probiotics for patients with hepatic encephalopathy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
15
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 2.   Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as
percentages across all included trials.
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Figure 3.   Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included
trial.
 
Allocation
Sequence generation was adequately performed in four trials (Bajaj
2008; Sharma 2008; Mittal 2009; Malaguarnera 2010), inadequately
performed in one trial (Liu 2004), and unclear in two trials
(Loguercio 1987; Pereg 2011).
No trial reported adequate allocation concealment. Two trials
reported inadequate allocation concealment (Bajaj 2008; Sharma
2008), and five trials were unclear about their method of allocation
concealment (Loguercio 1987; Liu 2004; Mittal 2009; Malaguarnera
2010; Pereg 2011).
Blinding
One trial adequately reported blinding of participants, outcome
assessors, and personnel (Loguercio 1987). One trial adequately
reported blinding of outcome assessors, but no blinding of
participants and personnel (Bajaj 2008). Two trials did not blind
participants, personnel, or outcome assessors (Sharma 2008; Mittal
2009). The remaining trials were unclear concerning the conduct of
blinding (Liu 2004; Malaguarnera 2010; Pereg 2011).
Incomplete outcome data
Incomplete outcome data were adequately addressed in one trial
(Bajaj 2008), inadequately in three (Loguercio 1987; Sharma 2008;
Pereg 2011), while the remainder were unclear (Liu 2004; Mittal
2009; Malaguarnera 2010).
Selective reporting
Two trials were free of selective outcome reporting (Bajaj 2008;
Sharma 2008), while the remainder were unclear (Loguercio 1987;
Liu 2004; Mittal 2009; Malaguarnera 2010; Pereg 2011).
Other potential sources of bias
Three trials declared their funding source (Loguercio 1987; Bajaj
2008; Pereg 2011). One of these trials was independently funded
(Bajaj 2008), and two were industry funded (Loguercio 1987; Pereg
2011). The remainder did not disclose their funding source (Liu
2004; Sharma 2008; Mittal 2009; Malaguarnera 2010).
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E;ects of interventions
See: Summary of findings for the main comparison Probiotic
versus placebo/ no intervention for patients with hepatic
encephalopathy; Summary of findings 2 Probiotic versus lactulose
for hepatic encephalopathy
Probiotic versus no treatment
Primary outcomes
There were no significant diKerences in all-cause mortality
(Analysis 1.1; 2 trials, 105 participants, RR 0.72, 95% CI 0.08 to
6.60) or in lack of recovery (Analysis 1.2; 4 trials, 206 participants:
RR 0.72; 95% CI 0.49 to 1.05). At one, two, and three months
there was no significant diKerences in number of adverse events
(Analysis 1.3; 3 trials, 145 participants: RR 0.34; 95% CI 0.08
to 1.42). There was no evidence of a diKerence in quality of
life (either physical or mental) at two months (Analysis 1.4; 1
trial, 20 participants contributed to the physical quality of life
measurement, 20 participants contributed to the mental quality of
life: MD Physical 0.00; 95% CI -5.47 to 5.47, MD Mental 4.00; 95% CI
-1.82 to 9.82).
Secondary outcomes
There were no significant diKerences in change of/or withdrawal
from treatment at one, two, and three months (Analysis 1.5; 3
trials, 175 participants: RR 1.28; 95% CI 0.52 to 3.19). No trial
reported sepsis as an outcome. Plasma ammonia concentration
was significantly lower for participants treated with probiotic than
with no intervention at one month (Analysis 1.6 (Analysis 1.6.1)); 3
trials, 226 participants: MD -2.99 μmol/L; 95% CI -5.70 to -0.29) but
not at two months when compared with no intervention (Analysis
1.6 (Analysis 1.6.2)); 3 trials, 181 participants: MD -1.82 μmol/L; 95%
CI -14.04 to 10.41). Plasma ammonia decreased the most at three
months in the participants treated with probiotic compared with no
intervention (Analysis 1.7; 1 trial, 73 participants: MD -6.79 μmol/L;
95% CI -10.39 to -3.19). Duration of hospital stay was not reported
in any trial.
Subgroup analysis
Subgroup analyses were performed for the outcomes 'no
recovery' (Analysis 1.2) and plasma ammonia concentration
(Analysis 1.6) using the prespecified subgroups (Subgroup analysis
and investigation of heterogeneity). Subgroup analyses could not
be performed by MELD score, as this was not reported in the trials.
Nor could it be performed by risk of bias, as all trials were judged as
suKering from high risk of bias.
No recovery
A significant diKerence was detected for the subgroup analysis on
duration of therapy (Analysis 1.10), test for subgroup diKerences:
Chi2 = 9.21, df = 2 (P = 0.01).
No significant diKerences were detected for the following subgroup
analyses: type of probiotic used (Analysis 1.8), test for subgroup
diKerences: Chi2 = 1.17, df = 1 (P = 0.28); grade of hepatic
encephalopathy (Analysis 1.9), test for subgroup diKerences: Chi2 =
1.93, df = 1 (P = 0.16); and co-interventions used (Analysis 1.11), test
for subgroup diKerences: Chi2 = 1.94, df = 2 (P = 0.38).
Plasma ammonia
No significant diKerences were detected for the following subgroup
analyses: type of probiotic used (Analysis 1.12), test for subgroup
diKerences: Chi2 = 1.83, df = 1 (P = 0.18); grade of hepatic
encephalopathy (Analysis 1.13), test for subgroup diKerences: Chi2
= 2.05, df = 1 (P = 0.15); duration of therapy (Analysis 1.14), test
for subgroup diKerences: Chi2 = 0.02, df = 1 (P = 0.87); and co-
interventions used (Analysis 1.15), test for subgroup diKerences:
Chi2 = 5.60, df = 2 (P = 0.06).
Heterogeneity
Heterogeneity was demonstrated for the outcome 'no recovery'
Analysis 1.2 (Chi2 = 6.93, df = 3; P=0.07, I2 = 57%) and
seemed largely attributable to duration of therapy (Analysis
1.10). Heterogeneity was demonstrated for the outcome plasma
ammonia concentration at two months Analysis 1.6 (Chi2 = 6.16,
df = 2; P = 0.05, I2 = 68%) and did not seem attributable to type
of probiotic used (Analysis 1.12), grade of hepatic encephalopathy
(Analysis 1.13), grade of hepatic encephalopathy (Analysis 1.13), or
co-interventions used (Analysis 1.15).
Probiotic versus lactulose
Primary outcomes
The three trials that compared probiotic with lactulose did not
report all-cause mortality (Mittal 2009 provided information about
mortality in the probiotic arm but not the lactulose arm), and we
were unable to obtain these data from the authors. There was no
significant diKerence in lack of recovery (Analysis 2.1; 3 trials, 173
participants: RR 1.05; 95% CI 0.75 to 1.47). There was no significant
diKerence in the number of adverse events (Analysis 2.2; 2 trials,
111 participants: RR 0.57; 95% CI 0.06 to 5.74). Quality of life was not
reported in either trial.
Secondary outcomes
There was no significant diKerence in change of/or withdrawal from
treatment at one month (Analysis 2.3; 3 trials, 190 participants: RR
1.10; 95% CI 0.40 to 3.03). There were no reports of septicaemia
attributable to probiotic in any trial. At one month there was no
significant diKerence in plasma ammonia concentration (Analysis
2.4; 2 trials, 93 participants: MD -6.61 μmol/L; 95% CI -30.05 to 16.84)
or change in plasma ammonia concentration (Analysis 2.5; 1 trial,
77 participants: MD 1.16 μmol/L; 95% CI -1.96 to 4.28). Duration of
hospital stay was not reported in any trial.
Subgroup analysis
Subgroup analyses were performed for the outcome plasma
ammonia concentration (Analysis 2.4) using the prespecified
subgroups (Subgroup analysis and investigation of heterogeneity).
Subgroup analyses could not be performed by MELD score, risk of
bias, co-interventions used or, duration of therapy as there was
no diKerences in these subgroups amongst the trials. Significant
diKerences were detected for the following subgroup analyses: type
of probiotic used (Analysis 2.6), test for subgroup diKerences: Chi2 =
6.15, df = 1 (P = 0.01) and grade of hepatic encephalopathy (Analysis
2.7), test for subgroup diKerences: Chi2 = 6.15, df = 1 (P = 0.01).
Heterogeneity
Heterogeneity was demonstrated for the outcome plasma
ammonia concentration Analysis 2.4 (Chi2 = 6.15, df = 1; P = 0.01,
I2 = 84%). Heterogeneity seemed largely attributable to the type of
probiotic used (Analysis 2.6) and grade of hepatic encephalopathy
(Analysis 2.7).
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D I S C U S S I O N
Summary of main results
We included seven trials in this review. Each trial used diKerent
probiotics (Table 1), and the duration of administration ranged
from 10 days to 180 days. The risk of bias of all the included trials
was high. No analysis demonstrated an advantage of probiotics
compared with no treatment on all-cause mortality, number
of adverse events, quality of life, or change of/or withdrawal
from treatment (while sepsis and duration of hospital stay were
unreported). When probiotics were compared with lactulose, no
analysis demonstrated a significant diKerence for any outcome
(while quality of life, septicaemia, and duration of hospital stay
were unreported). The use of probiotics compared with no
treatment suggested a statistically significant diKerence in plasma
ammonia concentration aOer one month (Analysis 1.6) and aOer
three months (Analysis 1.7).
Overall completeness and applicability of evidence
There were a small number of trials identified. Moreover,
the number of included patients were few. In the review,
trial populations and interventions varied widely across the
included trials. Outcomes were inconsistently reported as were
interventions, controls and associated treatments, for example,
dietary protein intake. Therefore, due to the lack of evidence of
a clinically important benefit with probiotics, their use currently
cannot be recommended.
Quality of the evidence
There is insuKicient evidence to draw meaningful conclusions
about the benefits and harms of probiotics in hepatic
encephalopathy. Overall, the methodological quality of trials was
far from optimal.
Potential biases in the review process
This systematic review with meta-analysis was undertaken with
broad inclusion criteria to assess the totality of available evidence.
Our literature search was comprehensive and did not exclude trials
based on language of publication or publication status. An attempt
was made to contact authors wherever trial data and methodology
was unclear. All data extraction and analysis were undertaken by
several authors working independently to minimise bias. Despite
these strengths, there were some limitations; for example, we
were not blinded to authorship during data extraction and risk of
bias assessment. While we did make an attempt to contact study
authors, it was not always certain if our messages were received and
we did not attempt to make any further contact if our initial emails
were not responded to. In addition, due to the small sample sizes of
the included trials, trial sequential analysis may have been a more
appropriate analytic technique (Thorlund 2009).
Agreements and disagreements with other studies or
reviews
A review published in 2011 discusses the eKect of prebiotics,
probiotics, and synbiotics in minimal hepatic encephalopathy
(Shukla 2011a). As our review did not look at the combination of
probiotics, prebiotics, and synbiotics, it is not possible to make
direct comparisons between the reviews. Of note, Shukla 2011a
were only able to locate two trials of probiotics compared to our
five trials including patients with minimal hepatic encephalopathy,
which suggests we utilised a more sensitive search strategy.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
We did not find convincing evidence that probiotics had a
significant beneficial or harmful eKect on patients with hepatic
encephalopathy. The methodological quality of trials to date are
far from optimal. Probiotics cannot be recommended based on the
findings of this review.
Implications for research
Hepatic encephalopathy has a poor clinical outcome and is a
significant burden on the health care system. Current treatment
options are of limited eKicacy. Probiotics represent a cheap
alternative option; however, their benefits and harms are still
uncertain and many fundamental questions concerning their
use remain. First, we need to assess the benefits and harms
of probiotics in randomised trials with low risk of systematic
errors ('bias') and low risk of random errors ('play of chance').
Moreover, it is unknown whether all probiotics are of equal
eKectiveness or what dose or duration of probiotic therapy is
necessary for treatment. It is also unknown whether colonisation
though multiple dosing is necessary for benefit or if a single
dose of probiotic would suKice (McGee 2010). Future research
should take these considerations into account and consider
alternative study designs; for example, factorial trials would allow
multiple comparisons to be made in the one trial. Future trials
should also adhere to the recently published ISHEN consensus
statement, which makes recommendations for trials in patients
with hepatic encephalopathy (Bajaj 2011). The human microbiome
project (Turnbaugh 2007) is one important initiative that will likely
contribute to a better understanding of the complex relationship
between humans and microbes.
The high response rate in the control arms of this review reflect the
natural history of hepatic encephalopathy, with its spontaneously
fluctuating nature and possibility for spontaneous remission.
Future trials should account for this when assessing the eKicacy
of interventions. It is also important that those conducting trials
also account for the time of day in which assessments are made.
Consideration should also be given to the type of placebo used;
for example, inactivated probiotic. All trials should at a minimum
assess important outcomes such as mortality, quality of life,
and adverse events. Trials should also be reported following the
CONSORT Statement http://www.consort-statement.org/.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Design: a prospective randomised trial with open allocation. 
A 2:1 randomisation to the treatment arm was performed. 
Trial duration: 60 days. 
Treatment duration: 60 days.
Participants Setting: outpatient single tertiary centre trial. 
Country: United States of America. 
Age range (years): 44 to 60. 
Total numbers randomised (group A/group B): 25 (17/8). 
Sex (M/F): not stated. 
Language: English. 
Stage/severity of hepatic encephalopathy: Child-Pugh score A/B/C: 22/3/0. 
Cause of hepatic encephalopathy: nonalcoholic etiology of cirrhosis.
Inclusions: nonalcoholic participants with cirrhosis with minimal hepatic encephalopathy. Defined by
no alcohol intake within 3 months of the trial and a nonalcoholic etiology of cirrhosis.
Exclusions: 
1. Alcohol use within 3 months.                                 
2. Alcoholic etiology of cirrhosis.                               
3. Current psychoactive medication use.                  
4. On current therapy for prevention or treatment of overt hepatic encephalopathy. 
5. Lack of English fluency. 
6. History of overt hepatic encephalopathy. 
7. Antibiotic use within 6 weeks of the trial. 
8. Diabetes mellitus.
Interventions Treatment group (A) probiotic yogurt: 
1. Streptococcus thermophilus (log 9 CFU/g on Day 0) for 60 days. 
2. Lactobacillus bulgaricus (log 8.7 CFU/g on Day 0) for 60 days. 
3. Lactobacillus acidophilus and Lactobacillus casei (log 5.9 CFU/g on Day 0) for 60 days. 
4. Bifidobacteria (log 5.2 CFU/g on Day 0) for 60 days. 
Participants received 12 ounces of yogurt a day. 
The specific probiotic used in this yogurt was Yo-Fast 88 manufactured by Chr-Hansen Inc in Denmark. 
Yogurt is manufactured by CC Jersey Crème, Spring Valley, Wisconsin.
Control group (B): no treatment.
Outcomes 1. Minimal hepatic encephalopathy reversal. 
2. Overt hepatic encephalopathy development. 
3. Adherence. 
4. Child-Pugh score. 
5. Meld score. 
6. SF-36 score. 
7. Venous ammonia. 
8. IL-6 and TNF-alpha levels.
Notes Contacted Prof. JS. Bajaj on the 14th of October 2010. Additional information provided by the author.
Risk of bias
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Bias Authors' judgement Support for judgement
Sequence generation Low risk Adequate sequence generation. A 2:1 randomisation was performed using a
random numbers table.
Allocation concealment High risk The treatment allocation was not concealed from the principal investigator.
Blinding 
Participants
High risk Participants knew whether they were in the treatment group or in the control
group.
Blinding 
Personnel
High risk The investigator knew whether a patient was included in the treatment group
or in the control group.
Blinding 
Outcome assessors
Low risk The outcome scorer was blinded.
Incomplete outcome data 
All outcomes
Low risk 3 out of 17 patients in the treatment group dropped out; 1 died from sepsis un-
related to the trial on day 67 but did not come to his first visit, and 2 did not
like the taste and dropped out on days 13 and 17, respectively.
2 out of 8 patients in the control group dropped out; they developed OHE on
days 22 and 35.
Primary analysis used an intention-to-treat analysis.
Selective outcome report-
ing
Low risk All outcomes mentioned in the methods (minimal hepatic encephalopathy
reversal, overt hepatic encephalopathy development and adherence) were
described in the results at baseline, after 30 days and after 60 days. Personal
communication with the author revealed no other outcomes were assessed.
Funding source Low risk The General Clinical Research Center at the Medical College of Wisconsin spon-
sored by the NIH supported this study.
Bajaj 2008  (Continued)
 
 
Methods Design: a parallel group randomised trial. 
Study duration: unknown. 
Treatment duration: 30 days.
Participants Setting: outpatient. 
Country: China. 
Age range (years): 43 to 69. 
Total numbers randomised (group A/group B/group C): 55 (20/20/15). 
Group C was not relevant to our analysis. 
Sex (M/F): 53/2. 
Language: English. 
Stage/severity of hepatic encephalopathy: Child-Pugh score A/B+C: 8/47. 
Cause of hepatic encephalopathy: patients with cirrhosis and hepatic encephalopathy without known
precipitants of hepatic encephalopathy, like renal impairment, alcohol related hepatic encephalopa-
thy, complicating hepatocellular carcinoma, etc.
Inclusions: 
1. Cirrhotic patients with minimal hepatic encephalopathy,  without over hepatic encephalopathy. 
2. Patients who had been abstinent from alcohol for at least two months, as corroborated by family
members and/or caregivers.
Exclusions: 
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1. Histological features of alcoholic hepatitis. 
2. A history within the previous six weeks of factors including infection, treatment with antibiotics, lac-
tulose or immunomodulatory drugs, and gastrointestinal haemorrhage. 
3. Other causes of reversible hepatic functional decompensation, such as drug-related hepatotoxicity
and choledocholithiasis. 
4. Other known precipitants of hepatic encephalopathy, including renal impairment, electrolyte imbal-
ance, and complicating hepatocellular carcinoma.
Interventions Treatment group (A) 
Oral supplementation with a synbiotic preparation containing Pediacoccus pentoseceus, Leuconostoc
mesenteroides, Lactobacillus paracasei and Lactobacillus plantarum (each probiotic at 1010 CFU's/day,
total dose of probiotics in a day: 4 x 1010 CFU's) plus 10 g of bioactive fermentable fibre (2.5 g beta glu-
can, 2.5 g inulin, 2.5 g pectin, 2.5 g resistant starch) for 30 days.
Treatment group (B) 
10 g of bioactive fermentable fibre (2.5 g beta glucan, 2.5 g inulin, 2.5 g pectin, 2.5 g resistant starch) for
30 days.
Control group (C) 
Placebo (non fermentable fibre) for 30 days.
Outcomes 1. Faecal pH. 
2. Venous ammonia levels. 
3. Serum endotoxin levels. 
4. Minimal hepatic encephalopathy status. 
5. Child-Pugh score. 
6. Adverse events. 
7. Overt hepatic encephalopathy development.
Notes Contacted Dr. Q. Liu on the 15th of October 2010, no response.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation High risk One sachet was randomly drawn from a pool for each patient, which is equiva-
lent to drawing lots. We feel that this does not represent best practice for ran-
domisation and so according to our predefined criteria have judged this cate-
gory as high risk of bias.
Allocation concealment Unclear risk Not stated.
Blinding 
Participants
Unclear risk Not stated for participants.
Blinding 
Personnel
Unclear risk Which sachets (A, B, or C) contained the synbiotic, fermentable fibre or non
fermentable fibre preparations was unknown to the investigators until after
the completion of the study and results had been analysed.
Blinding 
Outcome assessors
Unclear risk Not stated for outcome assessors.
Incomplete outcome data 
All outcomes
Unclear risk Unclear from the study.
Selective outcome report-
ing
Unclear risk Unclear from the study.
Funding source Unclear risk Not stated.
Liu 2004  (Continued)
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Methods Design: a parallel group randomised trial. 
Study duration: 23 days. 
Treatment duration: 10 days.
Participants Setting: outpatient. 
Country: Italy. 
Age range (years): 25 to 68. 
Total numbers randomised (group A/group B): 40 (20/20). 
Sex (M/F): 26/14. 
Language: English. 
Stage/severity of hepatic encephalopathy: grade I or II. 
Cause of hepatic encephalopathy: alcohol, hepatitis, cirrhosis.
Inclusions: cirrhotic patients with non-advanced hepatic encephalopathy (grade I or II).
Exclusions: 
1. HE degree > 2. 
2. Alcohol use at the moment of the study. 
3. Mental disorders and/or benzodiazepine use. 
4. Non compliance.
Interventions Treatment group (A) 
Enterococcus Lactic Acid bacteria strain SF68 (two capsules, each containing 75 x 106 CFU's, three
times daily, for 10 days) Bioflorin is a trade name of Giuliani and is distributed by Gipharmex SpA, Italy.
Control group (B) 
30 ml lactulose four times daily, for 10 days.
Outcomes 1. Mental state. 
2. Bowel function. 
3. Presence/absence abdominal pain. 
4. Blood ammonia level. 
5. Presence/absence meteorism. 
6. Reitan's test (number connection test). 
7. Adverse events.
Notes Additional information on risk of bias criteria provided by the author. Contacted Prof. C. Loguercio on
the 15th of October 2010.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Unclear risk Patients were randomly assigned to a treatment group. No further information
about randomisation.
Allocation concealment Unclear risk Information not provided.
Blinding 
Participants
Low risk Participants were blinded.
Blinding 
Personnel
Low risk Personnel was blinded.
Blinding 
Outcome assessors
Low risk The outcome scorer was blinded.
Loguercio 1987 
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Incomplete outcome data 
All outcomes
High risk All patients completed the treatment period. Five patients given lactulose and
four given Enterococcus SF68 did not arrive for post-treatment follow-up. On
day 15, two patients given lactulose were withdrawn from the study because
of marked hyperammonaemia and a worsening of hepatic encephalopathy.
Selective outcome report-
ing
Unclear risk Unclear from study.
Funding source High risk Gipharmex (Milan, Italy) supported this study.
Loguercio 1987  (Continued)
 
 
Methods Design: a double-blind parallel group randomised trial. 
Study duration: 2004 to 2007. 
Treatment duration: 60 days.
Participants Setting: inpatient. 
Country: Italy. 
Age range (years): not stated. 
Total numbers randomised (group A/group B): 125 (63/62). 
Sex (M/F): 62/63. 
Language: English. 
Stage/severity of hepatic encephalopathy: Child-Pugh score A/B/C: 46/59/20. 
Cause of hepatic encephalopathy: chronic hepatitis and cryptogenic cirrhosis with spontaneous hepat-
ic encephalopathy.
Inclusions: 
1. Chronic hepatitis with spontaneous manifest hepatic encephalopathy (mental state grade I or II. ac-
cording to the West-Haven criteria) and a Number Collection Test-A performance time > 30 seconds. 
2. Hyperammonemia (venous ammonia concentration > 50 mmol/l). 
3. Co-operative, hospitalised, adult patients with liver cirrhosis diagnosed by clinical, histological and
ultrasonographic findings (reduced dimensions of the liver as well as splenomegaly) and oesophageal
varices (stages II or III) observed by endoscopy.
Exclusions: 
1. Major complications of portal hypertension, such as gastrointestinal blood loss, hepatorenal syn-
drome or bacterial peritonitis. 
2. Acute superimposed liver injury. 
3. Other neurological disease and metabolic disorders such as alcoholism, diabetes mellitus, unbal-
anced heart failure and/or respiratory failure or end-stage renal disease. 
4. Severe hepatic encephalopathy (mental state grade III-IV). 
5. Administration of anti-hepatic encephalopathy medications such as neomycin, branched-chain
amino acids. 
6. Any additional precipitating factors such as high protein intake (additional high-protein meals),
constipation or intake of psychostimulants, sedatives, antidepressants, benzodiazepines or benzodi-
azepines antagonists (flumazenil). 
7. Fever, sepsis, or shock were also excluded to avoid variations caused by body temperature.
Interventions Treatment group (A) 
Bifidobacterium (subtype not stated) + (FOS) fructo-oligosaccharides for 60 days (dose not stated).
Control group (B) 
Lactulose for 60 days (dose not stated).
Note: FOS and lactulose were considered comparable because they are both complex carbohydrates,
which are indigestible to humans but digestible to bacteria. We were unable to locate any efficacy data
comparing FOS to lactulose in hepatic encephalopathy patients.
Malaguarnera 2010 
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Outcomes 1. Trail making test. 
2. Cognitive functions. 
3. Grade of hepatic encephalopathy. 
4. Child-Pugh score.
Notes Contacted Dr. M. Malaguarnera on the 15th of October 2010, no response.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk Randomisation was based on a computer-generated list.
Allocation concealment Unclear risk Stated it was a double-blind trial, but not for whom.
Blinding 
Participants
Unclear risk Stated it was a double-blind trial, but not for whom.
Blinding 
Personnel
Unclear risk Stated it was a double-blind trial, but not for whom.
Blinding 
Outcome assessors
Unclear risk Not stated for outcome assessors.
Incomplete outcome data 
All outcomes
Unclear risk Unclear from study.
Selective outcome report-
ing
Unclear risk Unclear from the study.
Funding source Unclear risk Not stated.
Malaguarnera 2010  (Continued)
 
 
Methods Design: a parallel randomised trial. 
Study duration: October 2007 to October 2009. 
Treatment duration: three months.
Participants Setting: outpatient. 
Country: India. 
Age range (years): 32 to 54. 
Total numbers randomised (group A/group B/group C/group D): 160 (40/40/40/40). 
We did not use group B and D in our analysis as these were not useful to compare to probiotics. 
Sex (M/F): 123/37. 
Language: English. 
Stage/severity of hepatic encephalopathy: not stated. 
Cause of hepatic encephalopathy: cirrhosis due to alcoholic liver disease, hepatitis B, hepatitis C or
other causes.
Inclusions: patients with cirrhosis who have minimal hepatic encephalopathy, diagnosed by two or
more abnormal (+2SD from the mean) psychometric tests.
Exclusions: 
1. Overt HE based on detailed neurological examination or history of overt HE in past 6 weeks. 
2. Recent history (< 6 wk) of gastrointestinal bleed. 
3. Active ongoing infection. 
4. Renal impairment with serum creatinine > 1.5mg%. 
Mittal 2009 
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5. Electrolyte impairment (S. Sodium < 130 or > 150 meq/dL, S. Potassium < 3.0 or > 5.5 meq/dL). 
6. Recent alcohol use (< 6wk) as reported by the patient, recent use of antibiotic, lactulose or LOLA (<
6wk), use of psychotropic drugs in last 6 weeks. 
7. TIPS, shunt surgery. 
8. Hepatocellular carcinoma. 
9. Severe co-morbidity as congestive heart failure, pulmonary disease, neurological & psychiatric prob-
lems impairing quality of life, or poor vision precluding neuropsychiatric assessment.
Interventions Control group (A) 
No treatment.
Treatment group (B) 
30ml to 60 ml lactulose twice daily for three months.
Treatment group (C) 
VSL#3 (containing Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifi-
dobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lac-
tobacillus bulgaricus) 110 billion CFU's twice daily for three months.
Treatment group (D) 
6 g (LOLA) L-ornithine L-aspartate three times daily for three months.
Outcomes 1. Minimal hepatic encephalopathy recovery. 
2. Minimal hepatic encephalopathy improvement. 
3. Arterial ammonia level. 
4. Development of overt hepatic encephalopathy. 
5. Sickness impact profile score (quality of life).
Notes Additional information on risk of bias criteria provided by the author. Contacted Prof. BC. Sharma on
the 14th of October 2010. 
Unpublished data provided by the author.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk Patients were randomised to one of the treatment groups using comput-
er-generated random tables.
Allocation concealment Unclear risk Not stated.
Blinding 
Participants
High risk Different way of administering for every treatment and therefore patients
knew which treatment they received.
Blinding 
Personnel
High risk Compliance was assessed primarily using pill and bottle count and therefore
blinding was not possible.
Blinding 
Outcome assessors
High risk Compliance was assessed primarily using pill and bottle count and therefore
blinding was not possible.
Incomplete outcome data 
All outcomes
Unclear risk 11 patients were lost to follow up, 3 from group A, 1 from group B, 3 from
group C, and 4 from group D. During treatment, 7 patients had to be admitted
to the hospital for causes other than overt hepatic encephalopathy. Of these 7
patients, 2 patients died, one each in group A and D.
Primary analysis used an intention-to-treat analysis, probably with imputa-
tion.
Mittal 2009  (Continued)
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Selective outcome report-
ing
Unclear risk Unclear from the trial.
Funding source Unclear risk Not stated.
Mittal 2009  (Continued)
 
 
Methods Design: a parallel randomised trial. 
Study duration: unclear. 
Treatment duration: six months.
Participants Setting: outpatient. 
Country: Israel. 
Age range (years): 53 to 74. 
Total numbers randomised (group A/group B): 40 (20/20). 
Sex (M/F): unclear. 
Language: English. 
Stage/severity of hepatic encephalopathy: minimal hepatic encephalopathy. 
Cause of hepatic encephalopathy: cirrhosis due to alcoholic liver disease, hepatitis B, hepatitis C or
other causes.
Inclusions: patients with liver cirrhosis and at least one major complication of cirrhosis in the past, clin-
ical evidence of portal hypertension, or decreased hepatic synthetic function.
Exclusions: 
1. Any sign of decompensation from any precipitant including gastrointestinal bleeding, infections,
acute renal failure, electrolyte impairment, or hepatocellular carcinoma.
2. Those chronically treated with antibiotics or lactulose.
3. Patients with alcoholic cirrhosis, for whom alcohol abstinence for at least 2 months prior to enrol-
ment could not be confirmed.
Interventions Control group (A) 
Wheat-based non-fermentable fiber placebo.
Treatment group (B) 
Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium bifidum, and Streptococcus ther-
mophiles (Bio-plus, Supherb, Israel), each at a daily dose of 2x1010 colony forming units.
Outcomes 1. Plasma ammonia.
2. Adverse events.
Notes Th study was registered in ClinicalTrials.gov (ID: NCT00312910).
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Unclear risk Not stated.
Allocation concealment Unclear risk Not stated.
Blinding 
Participants
Unclear risk Only stated in the title that the trial was double-blinded - no specific details
provided of who or how blinding was conducted.
Pereg 2011 
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Blinding 
Personnel
Unclear risk Only stated in the title that the trial was double-blinded - no specific details
provided of who or how blinding was conducted.
Blinding 
Outcome assessors
Unclear risk Only stated in the title that the trial was double-blinded - no specific details
provided of who or how blinding was conducted.
Incomplete outcome data 
All outcomes
High risk Four patients 'dropped out', no further details are provided.
Selective outcome report-
ing
Unclear risk Unclear from the trial.
Funding source High risk Supported by Supherb Ltd, Israel.
Pereg 2011  (Continued)
 
 
Methods Design: open-label randomised trial. 
Treatment duration: 1 month. 
Time period: February 2005 to August 2006.
Participants Setting: India. 
Age range (years): 30 to 54. 
Total numbers randomised (group A/group B/group C): 105 (35/35/35). 
Sex (M/F): 79/26. 
Language: English. 
Stage/severity of hepatic encephalopathy: Child-Pugh score A/B/C: 36/39/30. 
Cause of hepatic encephalopathy: cirrhosis due to alcohol consumption, chronic hepatitis and crypto-
genic cirrhosis.
Inclusions: cirrhotic patients with minimal hepatic encephalopathy without overt encephalopathy.
Exclusions: 
1. The presence of overt hepatic encephalopathy or history of hepatic encephalopathy. 
2. History of taking lactulose or any antibiotics. 
3. Alcohol intake.                          
4. Gastrointestinal haemorrhage or spontaneous bacterial peritonitis during the past six weeks. 
5. Earlier transjugular intrahepatic portosystemic shunt or shunt surgery. 
6. Significant comorbid illness such as heart failure, respiratory failure, or renal failure. 
7. Any neurologic diseases such as Alzheimer’s disease, Parkinson’s disease, and non hepatic metabolic
encephalopathies. 
8. Colour blindness and mature cataract, diabetic retinopathy and patients on psychoactive drugs,
such as antidepressants or sedatives.
Interventions Control group (A) 
30ml to 60 ml lactulose/day for one month.
Treatment group (B) 
One capsule (containing Streptococcus faecalis, Clostridium butyricum, Bacillus mesentricus, Lactic
acid bacillus) three times daily for one month, dose not stated.
Treatment group (C) 
30ml to 60 ml lactulose plus probiotics daily for one month.
Outcomes 1. Venous ammonia level. 
2. Child-Pugh score. 
3. Minimal hepatic encephalopathy recovery.
Sharma 2008 
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Notes Additional information provided by the author. Contacted Prof. BC. Sharma on the 14th of October
2010.
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk Patients were randomised according to a computer-generated randomisation
chart.
Allocation concealment High risk Trial personnel were able to view the allocation sequence.
Blinding 
Participants
High risk The trial was not blinded.
Blinding 
Personnel
High risk The trial was not blinded.
Blinding 
Outcome assessors
High risk The trial was not blinded.
Incomplete outcome data 
All outcomes
High risk Thirteen patients in the control group and five patients in the lactulose plus
probiotic group were lost to follow-up. Reasons are unclear.
Selective outcome report-
ing
Low risk All outcomes reported in the methods (Psychometric tests outcomes, P300 au-
ditory event-related potential, venous ammonia level and Child’s-Pugh classi-
fication) were measured and discussed on baseline and after one month. Per-
sonal communication with the author revealed no other outcomes were as-
sessed.
Funding source Unclear risk Not stated.
Sharma 2008  (Continued)
M = male.
F = female.
S = serum.
SD = standard deviation.
Wk = week.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adams 2006 No hepatic encephalopathy patients involved.
Al 2009 Not a randomised trial.
Albillos 2002 No hepatic encephalopathy patients involved.
Almeida 2006 Not a randomised trial.
Arya 2010 Not a randomised trial.
Bajaj 2008a Not a randomised trial.
Bajaj 2008b Not a randomised trial.
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Study Reason for exclusion
Ballongue 1997 No probiotic used.
Barclay 2011 Not a randomised trial.
Barreto-Zuniga 2001 No hepatic encephalopathy patients involved.
Bass 2007 Not a randomised trial.
Baumgart 2007 Not a randomised trial.
Behm 2006 Not a randomised trial.
Bengmark 2004 Not a randomised trial.
Bengmark 2006 Not a randomised trial.
Bengmark 2009 No hepatic encephalopathy patients involved.
Bereswill 2010 No probiotic used.
Bircher 1971 No probiotics used.
Bismuth 2011 Not a randomised trial.
Boca 2004 Not a randomised trial.
Bongaerts 2005 Not a randomised trial.
Burrowes 2005 No hepatic encephalopathy patients involved.
Buscher 2004 No hepatic encephalopathy patients involved.
Cabre 2005 Not a randomised trial.
Cachin 1969 No probiotics used.
Cada 2010 Not a randomised trial.
Calamita 2007 Not a randomised trial.
Cash 2010 Not a randomised trial.
Chadalavada 2010 Not a randomised trial.
Chen 2007 No probiotic used.
Colle 1989 Hepatic encephalopathy not confirmed.
Colman 1976 No probiotics used.
Conn 1970 Not a randomised trial.
Conn 1978 No probiotics used.
Crum 2005 Not a randomised trial.
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Study Reason for exclusion
Dasarathy 2003 No probiotic used.
Dbouk 2006 Not a randomised trial.
Demeter 2006 Not a randomised trial.
Dhiman 2004 Not a randomised trial.
Dhiman 2007 Not a randomised trial.
Dhiman 2009 Not a randomised trial.
Dhiman 2010 Not a randomised trial.
Diamant 2011 Not a randomised trial.
Diehl 2005 Not a randomised trial.
Diehl 2010 Not a randomised trial.
Doron 2005 Not a randomised trial.
Edmison 2007 Not a randomised trial.
Eguchi 2011 Not probiotic.
Elkington 1970 No probiotics used.
Esposito 2009 No humans involved.
Fan 2009 No hepatic encephalopathy patients involved.
Ferenci 2001 Not a randomised trial.
Ferenci 2007 Not a randomised trial.
Feret 2010 Not probiotic.
Ferreira 2010 Not a randomised trial.
Finney 2007 No probiotics used.
Foster 2010 Not a randomised trial.
Fujita 2008 No hepatic encephalopathy patients involved.
Fuster 2007 Not a randomised trial.
Garcia-Tsao 2003 Not a randomised trial.
Gratz 2010 Not a randomised trial.
Greco 2007 Groups non-comparable.
Gronbaek 2008 Not a randomised trial.
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Study Reason for exclusion
Guarner 2009 Not a randomised trial.
Guerrero 2008 Not a randomised trial.
Haemmerli 1969 Not a randomised trial.
Harding 2008 No hepatic encephalopathy patients.
Higashikawa 2010 No hepatic encephalopathy patients involved.
Hong 2009 No hepatic encephalopathy patients.
Hotten 2003 No hepatic encephalopathy patients involved.
Hulkova 2009 Not a randomised trial.
Iannitti 2010 Not a randomised trial.
Imler 1971 Not a randomised trial.
Jeejeebhoy 2004 Not a randomised trial.
Jia 2005 No hepatic encephalopathy patients involved.
Jiang 2008 No probiotics used.
Jonkers 2007 Not a randomised trial.
Kachaamy 2011 Not a randomised trial.
Kadayifci 2007 Not a randomised trial.
Karczewski 2010 No hepatic encephalopathy patients involved.
Keeffe 2007 Not a randomised trial.
Khan 2010 Not a randomised trial.
Kim 2008 No hepatic encephalopathy patients involved.
Kirpich 2008 No hepatic encephalopathy patients involved.
Koo 2010 Not a randomised trial.
Kramer 2004 Not a randomised trial.
Kremer 1974 Not a randomised trial.
Krueger 2004 Not a randomised trial.
Kumashiro 2008 Not a randomised trial.
Lata 2006 No hepatic encephalopathy patients involved.
Lata 2007 No hepatic encephalopathy patients involved.
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Study Reason for exclusion
Lata 2009 No hepatic encephalopathy patients involved.
Lawrence 2003 Not a randomised trial.
Li 2002 Not a randomised trial.
Lighthouse 2004 No hepatic encephalopathy patients involved.
Lirussi 2007 Not a randomised trial.
Liu 2010 Not a randomised trial.
Loguercio 2002 No hepatic encephalopathy patients involved.
Loguercio 2005 No hepatic encephalopathy patients involved.
Madsen 2008 No hepatic encephalopathy patients.
Malaguarnera 2007 Not a probiotic alone.
Marotta 2003 No hepatic encephalopathy patients involved.
Marteau 2001 Not a randomised trial.
Marteau 2002 Not a randomised trial.
Marteu 2001 Not a randomised trial.
McAvoy 2006 Not a randomised trial.
McClave 2009 Not a randomised trial.
Medina 2004 Not a randomised trial.
Meier 2005 Not a randomised trial.
Mencin 2009 Not a randomised trial.
Mennigen 2009 Not a randomised trial.
Michelfelder 2010 Not a randomised trial
Montgomery 2011 Not a randomised trial.
Montineri 2008 Not a randomised trial.
Montrose 2005 Not a randomised trial.
Moreno-Luna 2011 Not a randomised trial.
Morgan 2007 Not a randomised trial.
Mullen 2007 Not a randomised trial.
Muting 1972 No probiotics used.
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Study Reason for exclusion
Nair 2008 Abstract unavailable.
Narayan 2010 Not hepatic encephalopathy.
Nazir 2010 Prophylaxis not treatment.
Nolan 2010 Not a randomised trial.
Nomura 2007 No hepatic encephalopathy patients involved.
Norman 2008 Not a randomised trial.
O'Brien 2008 Not a randomised trial.
Oben 2008 Not a randomised trial.
Ojetti 2009 Not a randomised trial.
Okada 2010 Not a randomised trial.
Ooi 2010 No hepatic encephalopathy patients involved.
Oshea 2010 Not a randomised trial.
Pande 2009 No hepatic encephalopathy patients involved.
Park 2007 Not a randomised trial.
Phongsamran 2010 Not a randomised trial.
Pimentel-Nunes 2010 Not a randomised trial.
Portincasa 2005 Not a randomised trial.
Pradere 2010 Not a randomised trial.
Quercioli 2009 Not a randomised trial.
Quigley 2006 Not a randomised trial.
Rafiq 2009 Not a randomised trial.
Ratziu 2005 Not a randomised trial.
Rayes 2002 No hepatic encephalopathy patients involved.
Read 1966 Not a randomised trial.
Riddle 2008 No probiotics involved.
Rifatbegovic 2010 No hepatic encephalopathy patients involved.
Riggio 1990 No probiotic used.
Riggio 2009 Not a randomised trial.
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Study Reason for exclusion
Riordan 2003 No hepatic encephalopathy patients involved.
Riordan 2007 No hepatic encephalopathy patients involved.
Riordan 2010 No probiotic used.
Roberts 2006 Not a randomised trial.
Romero-Gomez 2010 Not a randomised trial.
Sanyal 2008 No probiotics used.
Scevola 1989 No probiotics used.
Schiano 2010 Not a randomised trial.
Seva-Pereira 2003 No hepatic encephalopathy patients involved.
Shawcross 2005 Not a randomised trial.
Sheth 2008 Not a randomised trial.
Shin 2010 Not a randomised trial.
Shukla 2009 Not a randomised trial
Shukla 2011 Not a randomised trial.
Simons 2006 Not hepatic encephalopathy.
Solga 2003 Not a randomised trial
Sotelo 2010 Not a randomised trial.
Stadlbauer 2008 No hepatic encephalopathy patients involved.
Stewart 2003 Not a randomised trial.
Stewart 2007 Not a randomised trial.
Story 2010 Not a randomised trial.
Strauss 2006 Not a randomised trial.
Sun 2007 Not a randomised trial.
Sundaram 2009 Not a randomised trial.
Szabo 2010 Not a randomised trial.
Szilagyi 2004 Not a randomised trial.
Tandon 2009 Not a randomised trial.
Tarao 1995 No probiotics used.
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Study Reason for exclusion
Thoma 2003 Not a randomised trial.
Tolman 2007 Not a randomised trial.
Toris 2011 Not a randomised trial.
Valenti 2009 Not a randomised trial.
Van Erpecum 2006 Not a randomised trial.
Vanovski 1975 Not a randomised trial.
Vince 1974 No probiotics used.
Vinnitskaia 2008 Not a randomised trial.
Vleggaar 2008 No hepatic encephalopathy patients involved.
Wierzbicka 2008 Not a randomised trial.
Wilbur 2009 Not a randomised trial.
Wright 2007 Not a randomised trial.
Wu 2008 Not a randomised trial.
Xu 2009 No hepatic encephalopathy patients involved.
Yakabe 2009 No hepatic encephalopathy patients involved.
Yoshikawa 2006 Not a randomised trial.
Younossi 2008 Not a randomised trial.
Zafirova 2010 Not a randomised trial
Zhang 2006 Not a randomised trial.
Zhao 2004 No hepatic encephalopathy patients involved.
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: an Open Label, Randomized Con-
trolled Trial of Lactulose, Probiotics, and No-therapy.
Methods Phase IV study.
The investigators will assess the effects of lactulose and probiotics for the prevention of recur-
rence of HE (secondary prophylaxis) in patients after the recovery of an episode of overt hepatic
encephalopathy.
Sharma 2010 
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One treatment group receives lactulose and the other treatment group receives probiotics for six
months.
Participants Patients with cirrhosis and previous history of recovery from hepatic encephalopathy, between 18
and 75 years old.
Interventions Treatment group (A): lactulose (30ml to 60 ml of lactulose in 2 or 3 divided doses so that patient
passed 2 to 3 semi soO stools per day). 
Treatment group (B): probiotics: VSL#3 (110 billion CFU's three times a day).
Outcomes Primary outcome: episode of overt hepatic encephalopathy. 
Secondary outcome: side effects to therapy.
Starting date September 2008.
Contact information G B Pant Hospital, New Delhi, Delhi, India, 110002.
Contact: Barjesh C Sharma, MD, DM. tel.  9718599203; drbcsharma@hotmail.com     
Principal Investigator: Barjesh C Sharma, MD,DM.         
Notes Data obtained from trial registry ClinicalTrials.gov, ID: NCT01178372.
Sharma 2010  (Continued)
Abbreviations: tel.-telephone.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Probiotic versus placebo/ no intervention
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 All cause mortality 2 105 Risk Ratio (M-H, Random, 95%
CI)
0.72 [0.08, 6.60]
1.1 2 months 1 25 Risk Ratio (M-H, Random, 95%
CI)
1.5 [0.07, 33.26]
1.2 3 months 1 80 Risk Ratio (M-H, Random, 95%
CI)
0.33 [0.01, 7.95]
2 No recovery (incomplete resolution of
clinical symptoms)
4 206 Risk Ratio (M-H, Random, 95%
CI)
0.72 [0.49, 1.05]
2.1 1 month 2 101 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.64, 1.48]
2.2 2 months 1 25 Risk Ratio (M-H, Random, 95%
CI)
0.32 [0.16, 0.66]
2.3 3 months 1 80 Risk Ratio (M-H, Random, 95%
CI)
0.72 [0.56, 0.93]
3 Number of adverse events 3 145 Risk Ratio (M-H, Random, 95%
CI)
0.34 [0.08, 1.42]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3.1 1 month 1 40 Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
3.2 2 months 1 25 Risk Ratio (M-H, Random, 95%
CI)
0.10 [0.01, 1.87]
3.3 3 months 1 80 Risk Ratio (M-H, Random, 95%
CI)
0.5 [0.10, 2.58]
4 Quality of life SF-36 physical/ mental 1   Mean Difference (IV, Random,
95% CI)
Totals not selected
4.1 Physical 2 months 1   Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
4.2 Mental 2 months 1   Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
5 Change of/or withdrawal from treat-
ment
3 175 Risk Ratio (M-H, Random, 95%
CI)
1.28 [0.52, 3.19]
5.1 1 month 1 70 Risk Ratio (M-H, Random, 95%
CI)
1.25 [0.37, 4.27]
5.2 2 months 1 25 Risk Ratio (M-H, Random, 95%
CI)
3.5 [0.20, 60.70]
5.3 3 months 1 80 Risk Ratio (M-H, Random, 95%
CI)
1.0 [0.21, 4.66]
6 Plasma ammonia concentration
(μmol/L)
5   Mean Difference (IV, Random,
95% CI)
Subtotals only
6.1 1 month 3 226 Mean Difference (IV, Random,
95% CI)
-2.99 [-5.70, -0.29]
6.2 2 months 3 181 Mean Difference (IV, Random,
95% CI)
-1.82 [-14.04, 10.41]
7 Change in plasma ammonia concen-
tration (μmol/L)
1   Mean Difference (IV, Random,
95% CI)
Totals not selected
7.1 3 months 1   Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
8 No recovery (subgroup type of probi-
otic used)
4 206 Risk Ratio (M-H, Random, 95%
CI)
0.72 [0.49, 1.05]
8.1 Lactobacillus 1 40 Risk Ratio (M-H, Random, 95%
CI)
1.0 [0.54, 1.86]
8.2 Mixed 3 166 Risk Ratio (M-H, Random, 95%
CI)
0.65 [0.40, 1.05]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
9 No recovery (subgroup grade of hepat-
ic encephalopathy)
4 206 Risk Ratio (M-H, Random, 95%
CI)
0.72 [0.49, 1.05]
9.1 Minimal 2 105 Risk Ratio (M-H, Random, 95%
CI)
0.52 [0.23, 1.15]
9.2 Overt 2 101 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.64, 1.48]
10 No recovery (subgroup duration of
therapy)
4 206 Risk Ratio (M-H, Random, 95%
CI)
0.80 [0.51, 1.25]
10.1 1 month and less 2 101 Risk Ratio (M-H, Random, 95%
CI)
0.98 [0.64, 1.48]
10.2 Between 1 and 2 months 1 25 Risk Ratio (M-H, Random, 95%
CI)
0.32 [0.16, 0.66]
10.3 More than 2 months 1 80 Risk Ratio (M-H, Random, 95%
CI)
1.0 [0.86, 1.16]
11 No recovery (subgroup co-interven-
tions used)
4 206 Risk Ratio (M-H, Random, 95%
CI)
0.72 [0.49, 1.05]
11.1 No treatment 2 105 Risk Ratio (M-H, Random, 95%
CI)
0.52 [0.23, 1.15]
11.2 Bioactive fermentable fibre 1 40 Risk Ratio (M-H, Random, 95%
CI)
1.0 [0.54, 1.86]
11.3 Lactulose 1 61 Risk Ratio (M-H, Random, 95%
CI)
0.96 [0.55, 1.69]
12 Plasma ammonia concentration
(subgroup type of probiotic used)
4 279 Mean Difference (IV, Random,
95% CI)
-4.47 [-10.62, 1.69]
12.1 Bifidobacterium 1 125 Mean Difference (IV, Random,
95% CI)
-9.35 [-16.09, -2.61]
12.2 Mixed 3 154 Mean Difference (IV, Random,
95% CI)
-0.72 [-11.23, 9.79]
13 Plasma ammonia concentra-
tion (subgroup grade of hepatic en-
cephalopathy)
5 315 Mean Difference (IV, Random,
95% CI)
-4.71 [-9.97, 0.56]
13.1 Minimal 4 190 Mean Difference (IV, Random,
95% CI)
-1.80 [-9.65, 6.06]
13.2 Overt 1 125 Mean Difference (IV, Random,
95% CI)
-9.35 [-16.09, -2.61]
14 Plasma ammonia concentration
(subgroup duration of therapy)
5 282 Mean Difference (IV, Random,
95% CI)
-3.10 [-8.15, 1.96]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
14.1 1 month and less 2 101 Mean Difference (IV, Random,
95% CI)
-2.82 [-5.63, -0.02]
14.2 Between 1 and 2 months 3 181 Mean Difference (IV, Random,
95% CI)
-1.82 [-14.04, 10.41]
15 Plasma ammonia concentration
(subgroup co-interventions used)
4 246 Mean Difference (IV, Random,
95% CI)
-2.86 [-8.79, 3.07]
15.1 No treatment 1 20 Mean Difference (IV, Random,
95% CI)
10.0 [-3.83, 23.83]
15.2 Bioactive fermentable fibre 1 40 Mean Difference (IV, Random,
95% CI)
-2.90 [-5.51, -0.29]
15.3 Lactulose 2 186 Mean Difference (IV, Random,
95% CI)
-7.88 [-14.29, -1.47]
 
 
Analysis 1.1.   Comparison 1 Probiotic versus placebo/ no intervention, Outcome 1 All cause mortality.
Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.1.1 2 months  
Bajaj 2008 1/17 0/8 51.15% 1.5[0.07,33.26]
Subtotal (95% CI) 17 8 51.15% 1.5[0.07,33.26]
Total events: 1 (Probiotic), 0 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.26(P=0.8)  
   
1.1.2 3 months  
Mittal 2009 0/40 1/40 48.85% 0.33[0.01,7.95]
Subtotal (95% CI) 40 40 48.85% 0.33[0.01,7.95]
Total events: 0 (Probiotic), 1 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.68(P=0.5)  
   
Total (95% CI) 57 48 100% 0.72[0.08,6.6]
Total events: 1 (Probiotic), 1 (No intervention)  
Heterogeneity: Tau2=0; Chi2=0.44, df=1(P=0.51); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
Test for subgroup differences: Chi2=0.44, df=1 (P=0.51), I2=0%  
Favours probiotic 2000.005 100.1 1 Favours control
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Analysis 1.2.   Comparison 1 Probiotic versus placebo/ no intervention,
Outcome 2 No recovery (incomplete resolution of clinical symptoms).
Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.2.1 1 month  
Liu 2004 10/20 10/20 20.92% 1[0.54,1.86]
Sharma 2008 13/30 14/31 23.07% 0.96[0.55,1.69]
Subtotal (95% CI) 50 51 43.99% 0.98[0.64,1.48]
Total events: 23 (Probiotic), 24 (No intervention)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%  
Test for overall effect: Z=0.11(P=0.92)  
   
1.2.2 2 months  
Bajaj 2008 5/17 8/8 17.77% 0.32[0.16,0.66]
Subtotal (95% CI) 17 8 17.77% 0.32[0.16,0.66]
Total events: 5 (Probiotic), 8 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.1(P=0)  
   
1.2.3 3 months  
Mittal 2009 26/40 36/40 38.24% 0.72[0.56,0.93]
Subtotal (95% CI) 40 40 38.24% 0.72[0.56,0.93]
Total events: 26 (Probiotic), 36 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.55(P=0.01)  
   
Total (95% CI) 107 99 100% 0.72[0.49,1.05]
Total events: 54 (Probiotic), 68 (No intervention)  
Heterogeneity: Tau2=0.08; Chi2=6.93, df=3(P=0.07); I2=56.72%  
Test for overall effect: Z=1.7(P=0.09)  
Test for subgroup differences: Chi2=6.88, df=1 (P=0.03), I2=70.92%  
Favours probiotic 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.3.   Comparison 1 Probiotic versus placebo/ no intervention, Outcome 3 Number of adverse events.
Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 1 month  
Liu 2004 0/20 0/20   Not estimable
Subtotal (95% CI) 20 20 Not estimable
Total events: 0 (Probiotic), 0 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.3.2 2 months  
Bajaj 2008 0/17 2/8 23.86% 0.1[0.01,1.87]
Subtotal (95% CI) 17 8 23.86% 0.1[0.01,1.87]
Total events: 0 (Probiotic), 2 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.54(P=0.12)  
   
Favours probiotic 2000.005 100.1 1 Favours control
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Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.3 3 months  
Mittal 2009 2/40 4/40 76.14% 0.5[0.1,2.58]
Subtotal (95% CI) 40 40 76.14% 0.5[0.1,2.58]
Total events: 2 (Probiotic), 4 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.83(P=0.41)  
   
Total (95% CI) 77 68 100% 0.34[0.08,1.42]
Total events: 2 (Probiotic), 6 (No intervention)  
Heterogeneity: Tau2=0; Chi2=0.89, df=1(P=0.35); I2=0%  
Test for overall effect: Z=1.48(P=0.14)  
Test for subgroup differences: Chi2=0.88, df=1 (P=0.35), I2=0%  
Favours probiotic 2000.005 100.1 1 Favours control
 
 
Analysis 1.4.   Comparison 1 Probiotic versus placebo/ no
intervention, Outcome 4 Quality of life SF-36 physical/ mental.
Study or subgroup Probiotic No intervention Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
1.4.1 Physical 2 months  
Bajaj 2008 14 39 (5) 6 39 (6) 0[-5.47,5.47]
   
1.4.2 Mental 2 months  
Bajaj 2008 14 46 (3) 6 42 (7) 4[-1.82,9.82]
Favours placebo 4020-40 -20 0 Favours control
 
 
Analysis 1.5.   Comparison 1 Probiotic versus placebo/ no
intervention, Outcome 5 Change of/or withdrawal from treatment.
Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.5.1 1 month  
Sharma 2008 5/35 4/35 54.87% 1.25[0.37,4.27]
Subtotal (95% CI) 35 35 54.87% 1.25[0.37,4.27]
Total events: 5 (Probiotic), 4 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
   
1.5.2 2 months  
Bajaj 2008 3/17 0/8 10.17% 3.5[0.2,60.7]
Subtotal (95% CI) 17 8 10.17% 3.5[0.2,60.7]
Total events: 3 (Probiotic), 0 (No intervention)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.86(P=0.39)  
   
1.5.3 3 months  
Mittal 2009 3/40 3/40 34.96% 1[0.21,4.66]
Favours probiotic 500.02 100.1 1 Favours control
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Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 40 40 34.96% 1[0.21,4.66]
Total events: 3 (Probiotic), 3 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 92 83 100% 1.28[0.52,3.19]
Total events: 11 (Probiotic), 7 (No intervention)  
Heterogeneity: Tau2=0; Chi2=0.59, df=2(P=0.75); I2=0%  
Test for overall effect: Z=0.54(P=0.59)  
Test for subgroup differences: Chi2=0.58, df=1 (P=0.75), I2=0%  
Favours probiotic 500.02 100.1 1 Favours control
 
 
Analysis 1.6.   Comparison 1 Probiotic versus placebo/ no
intervention, Outcome 6 Plasma ammonia concentration (μmol/L).
Study or subgroup Probiotic No intervention Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.6.1 1 month  
Sharma 2008 30 68.7 (28.4) 31 69.3 (33.3) 3.04% -0.6[-16.11,14.91]
Malaguarnera 2010 63 66.2 (28.8) 62 71.5 (29.8) 6.92% -5.25[-15.53,5.03]
Liu 2004 20 38.6 (3.9) 20 41.5 (5.2) 90.04% -2.9[-5.75,-0.05]
Subtotal *** 113   113   100% -2.99[-5.7,-0.29]
Heterogeneity: Tau2=0; Chi2=0.28, df=2(P=0.87); I2=0%  
Test for overall effect: Z=2.17(P=0.03)  
   
1.6.2 2 months  
Pereg 2011 18 42.1 (26.9) 18 45.2 (23.6) 26.12% -3.1[-19.63,13.43]
Bajaj 2008 14 50 (26) 6 40 (3) 30.49% 10[-3.83,23.83]
Malaguarnera 2010 63 55.9 (15.5) 62 65.3 (22.3) 43.39% -9.35[-16.09,-2.61]
Subtotal *** 95   86   100% -1.82[-14.04,10.41]
Heterogeneity: Tau2=77.83; Chi2=6.16, df=2(P=0.05); I2=67.51%  
Test for overall effect: Z=0.29(P=0.77)  
Favours probiotic 10050-100 -50 0 Favours control
 
 
Analysis 1.7.   Comparison 1 Probiotic versus placebo/ no intervention,
Outcome 7 Change in plasma ammonia concentration (μmol/L).
Study or subgroup Probiotic No intervention Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
1.7.1 3 months  
Mittal 2009 37 -7.3 (7.9) 36 -0.5 (7.8) -6.79[-10.39,-3.19]
Favours probiotic 2010-20 -10 0 Favours control
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Analysis 1.8.   Comparison 1 Probiotic versus placebo/ no intervention,
Outcome 8 No recovery (subgroup type of probiotic used).
Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.8.1 Lactobacillus  
Liu 2004 10/20 10/20 20.92% 1[0.54,1.86]
Subtotal (95% CI) 20 20 20.92% 1[0.54,1.86]
Total events: 10 (Probiotic), 10 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.8.2 Mixed  
Bajaj 2008 5/17 8/8 17.77% 0.32[0.16,0.66]
Sharma 2008 13/30 14/31 23.07% 0.96[0.55,1.69]
Mittal 2009 26/40 36/40 38.24% 0.72[0.56,0.93]
Subtotal (95% CI) 87 79 79.08% 0.65[0.4,1.05]
Total events: 44 (Probiotic), 58 (No intervention)  
Heterogeneity: Tau2=0.12; Chi2=5.75, df=2(P=0.06); I2=65.21%  
Test for overall effect: Z=1.76(P=0.08)  
   
Total (95% CI) 107 99 100% 0.72[0.49,1.05]
Total events: 54 (Probiotic), 68 (No intervention)  
Heterogeneity: Tau2=0.08; Chi2=6.93, df=3(P=0.07); I2=56.72%  
Test for overall effect: Z=1.7(P=0.09)  
Test for subgroup differences: Chi2=1.17, df=1 (P=0.28), I2=14.74%  
Favours probiotic 50.2 20.5 1 Favours control
 
 
Analysis 1.9.   Comparison 1 Probiotic versus placebo/ no intervention,
Outcome 9 No recovery (subgroup grade of hepatic encephalopathy).
Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.9.1 Minimal  
Bajaj 2008 5/17 8/8 17.77% 0.32[0.16,0.66]
Mittal 2009 26/40 36/40 38.24% 0.72[0.56,0.93]
Subtotal (95% CI) 57 48 56.01% 0.52[0.23,1.15]
Total events: 31 (Probiotic), 44 (No intervention)  
Heterogeneity: Tau2=0.26; Chi2=4.53, df=1(P=0.03); I2=77.93%  
Test for overall effect: Z=1.63(P=0.1)  
   
1.9.2 Overt  
Liu 2004 10/20 10/20 20.92% 1[0.54,1.86]
Sharma 2008 13/30 14/31 23.07% 0.96[0.55,1.69]
Subtotal (95% CI) 50 51 43.99% 0.98[0.64,1.48]
Total events: 23 (Probiotic), 24 (No intervention)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%  
Test for overall effect: Z=0.11(P=0.92)  
   
Total (95% CI) 107 99 100% 0.72[0.49,1.05]
Total events: 54 (Probiotic), 68 (No intervention)  
Heterogeneity: Tau2=0.08; Chi2=6.93, df=3(P=0.07); I2=56.72%  
Favours probiotic 100.1 50.2 20.5 1 Favours control
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Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=1.7(P=0.09)  
Test for subgroup differences: Chi2=1.93, df=1 (P=0.16), I2=48.16%  
Favours probiotic 100.1 50.2 20.5 1 Favours control
 
 
Analysis 1.10.   Comparison 1 Probiotic versus placebo/ no
intervention, Outcome 10 No recovery (subgroup duration of therapy).
Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.10.1 1 month and less  
Liu 2004 10/20 10/20 21.73% 1[0.54,1.86]
Sharma 2008 13/30 14/31 23.41% 0.96[0.55,1.69]
Subtotal (95% CI) 50 51 45.14% 0.98[0.64,1.48]
Total events: 23 (Probiotic), 24 (No intervention)  
Heterogeneity: Tau2=0; Chi2=0.01, df=1(P=0.92); I2=0%  
Test for overall effect: Z=0.11(P=0.92)  
   
1.10.2 Between 1 and 2 months  
Bajaj 2008 5/17 8/8 19.13% 0.32[0.16,0.66]
Subtotal (95% CI) 17 8 19.13% 0.32[0.16,0.66]
Total events: 5 (Probiotic), 8 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.1(P=0)  
   
1.10.3 More than 2 months  
Mittal 2009 36/40 36/40 35.73% 1[0.86,1.16]
Subtotal (95% CI) 40 40 35.73% 1[0.86,1.16]
Total events: 36 (Probiotic), 36 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 107 99 100% 0.8[0.51,1.25]
Total events: 64 (Probiotic), 68 (No intervention)  
Heterogeneity: Tau2=0.14; Chi2=10.57, df=3(P=0.01); I2=71.6%  
Test for overall effect: Z=0.99(P=0.32)  
Test for subgroup differences: Chi2=9.21, df=1 (P=0.01), I2=78.29%  
Favours probiotic 50.2 20.5 1 Favours control
 
 
Analysis 1.11.   Comparison 1 Probiotic versus placebo/ no intervention,
Outcome 11 No recovery (subgroup co-interventions used).
Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.11.1 No treatment  
Bajaj 2008 5/17 8/8 17.77% 0.32[0.16,0.66]
Mittal 2009 26/40 36/40 38.24% 0.72[0.56,0.93]
Subtotal (95% CI) 57 48 56.01% 0.52[0.23,1.15]
Favours control 50.2 20.5 1 Favours probiotic
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Study or subgroup Probiotic No intervention Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 31 (Probiotic), 44 (No intervention)  
Heterogeneity: Tau2=0.26; Chi2=4.53, df=1(P=0.03); I2=77.93%  
Test for overall effect: Z=1.63(P=0.1)  
   
1.11.2 Bioactive fermentable fibre  
Liu 2004 10/20 10/20 20.92% 1[0.54,1.86]
Subtotal (95% CI) 20 20 20.92% 1[0.54,1.86]
Total events: 10 (Probiotic), 10 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.11.3 Lactulose  
Sharma 2008 13/30 14/31 23.07% 0.96[0.55,1.69]
Subtotal (95% CI) 30 31 23.07% 0.96[0.55,1.69]
Total events: 13 (Probiotic), 14 (No intervention)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.14(P=0.89)  
   
Total (95% CI) 107 99 100% 0.72[0.49,1.05]
Total events: 54 (Probiotic), 68 (No intervention)  
Heterogeneity: Tau2=0.08; Chi2=6.93, df=3(P=0.07); I2=56.72%  
Test for overall effect: Z=1.7(P=0.09)  
Test for subgroup differences: Chi2=1.94, df=1 (P=0.38), I2=0%  
Favours control 50.2 20.5 1 Favours probiotic
 
 
Analysis 1.12.   Comparison 1 Probiotic versus placebo/ no intervention,
Outcome 12 Plasma ammonia concentration (subgroup type of probiotic used).
Study or subgroup Probiotic No intervention Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.12.1 Bifidobacterium  
Malaguarnera 2010 63 55.9 (15.5) 62 65.3 (22.3) 31.22% -9.35[-16.09,-2.61]
Subtotal *** 63   62   31.22% -9.35[-16.09,-2.61]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.72(P=0.01)  
   
1.12.2 Mixed  
Sharma 2008 30 68.7 (28.4) 31 69.3 (33.3) 11.98% -0.6[-16.11,14.91]
Bajaj 2008 14 50 (26) 6 40 (3) 14.19% 10[-3.83,23.83]
Mittal 2009 37 -7.3 (7.9) 36 -0.5 (7.8) 42.61% -6.79[-10.39,-3.19]
Subtotal *** 81   73   68.78% -0.72[-11.23,9.79]
Heterogeneity: Tau2=55.91; Chi2=5.7, df=2(P=0.06); I2=64.92%  
Test for overall effect: Z=0.13(P=0.89)  
   
Total *** 144   135   100% -4.47[-10.62,1.69]
Heterogeneity: Tau2=19.8; Chi2=6.71, df=3(P=0.08); I2=55.3%  
Test for overall effect: Z=1.42(P=0.16)  
Test for subgroup differences: Chi2=1.83, df=1 (P=0.18), I2=45.5%  
Favours probiotic 2010-20 -10 0 Favours control
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Analysis 1.13.   Comparison 1 Probiotic versus placebo/ no intervention, Outcome
13 Plasma ammonia concentration (subgroup grade of hepatic encephalopathy).
Study or subgroup Probiotic No intervention Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.13.1 Minimal  
Pereg 2011 18 42.1 (26.9) 18 45.2 (23.6) 8.51% -3.1[-19.63,13.43]
Sharma 2008 30 68.7 (28.4) 31 69.3 (33.3) 9.45% -0.6[-16.11,14.91]
Bajaj 2008 14 50 (26) 6 40 (3) 11.37% 10[-3.83,23.83]
Mittal 2009 37 -7.3 (7.9) 36 -0.5 (7.8) 42.36% -6.79[-10.39,-3.19]
Subtotal *** 99   91   71.7% -1.8[-9.65,6.06]
Heterogeneity: Tau2=30.7; Chi2=5.78, df=3(P=0.12); I2=48.08%  
Test for overall effect: Z=0.45(P=0.65)  
   
1.13.2 Overt  
Malaguarnera 2010 63 55.9 (15.5) 62 65.3 (22.3) 28.3% -9.35[-16.09,-2.61]
Subtotal *** 63   62   28.3% -9.35[-16.09,-2.61]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.72(P=0.01)  
   
Total *** 162   153   100% -4.71[-9.97,0.56]
Heterogeneity: Tau2=13.65; Chi2=6.85, df=4(P=0.14); I2=41.59%  
Test for overall effect: Z=1.75(P=0.08)  
Test for subgroup differences: Chi2=2.05, df=1 (P=0.15), I2=51.14%  
Favours probiotic 2010-20 -10 0 Favours control
 
 
Analysis 1.14.   Comparison 1 Probiotic versus placebo/ no intervention,
Outcome 14 Plasma ammonia concentration (subgroup duration of therapy).
Study or subgroup Probiotic No intervention Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.14.1 1 month and less  
Liu 2004 20 38.6 (3.9) 20 41.5 (5.2) 45.32% -2.9[-5.75,-0.05]
Sharma 2008 30 68.7 (28.4) 31 69.3 (33.3) 8.83% -0.6[-16.11,14.91]
Subtotal *** 50   51   54.16% -2.82[-5.63,-0.02]
Heterogeneity: Tau2=0; Chi2=0.08, df=1(P=0.78); I2=0%  
Test for overall effect: Z=1.98(P=0.05)  
   
1.14.2 Between 1 and 2 months  
Bajaj 2008 14 50 (26) 6 40 (3) 10.66% 10[-3.83,23.83]
Malaguarnera 2010 63 55.9 (15.5) 62 65.3 (22.3) 27.25% -9.35[-16.09,-2.61]
Pereg 2011 18 42.1 (26.9) 18 45.2 (23.6) 7.94% -3.1[-19.63,13.43]
Subtotal *** 95   86   45.84% -1.82[-14.04,10.41]
Heterogeneity: Tau2=77.83; Chi2=6.16, df=2(P=0.05); I2=67.51%  
Test for overall effect: Z=0.29(P=0.77)  
   
Total *** 145   137   100% -3.1[-8.15,1.96]
Heterogeneity: Tau2=12.55; Chi2=6.84, df=4(P=0.14); I2=41.51%  
Test for overall effect: Z=1.2(P=0.23)  
Test for subgroup differences: Chi2=0.02, df=1 (P=0.87), I2=0%  
Favours probiotic 2010-20 -10 0 Favours control
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Analysis 1.15.   Comparison 1 Probiotic versus placebo/ no intervention,
Outcome 15 Plasma ammonia concentration (subgroup co-interventions used).
Study or subgroup Probiotic No intervention Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.15.1 No treatment  
Bajaj 2008 14 50 (26) 6 40 (3) 13.4% 10[-3.83,23.83]
Subtotal *** 14   6   13.4% 10[-3.83,23.83]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.42(P=0.16)  
   
1.15.2 Bioactive fermentable fibre  
Liu 2004 20 38.6 (2.9) 20 41.5 (5.2) 45.16% -2.9[-5.51,-0.29]
Subtotal *** 20   20   45.16% -2.9[-5.51,-0.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.18(P=0.03)  
   
1.15.3 Lactulose  
Sharma 2008 30 68.7 (28.4) 31 69.3 (33.3) 11.27% -0.6[-16.11,14.91]
Malaguarnera 2010 63 55.9 (15.5) 62 65.3 (22.3) 30.17% -9.35[-16.09,-2.61]
Subtotal *** 93   93   41.44% -7.88[-14.29,-1.47]
Heterogeneity: Tau2=1.04; Chi2=1.03, df=1(P=0.31); I2=2.71%  
Test for overall effect: Z=2.41(P=0.02)  
   
Total *** 127   119   100% -2.86[-8.79,3.07]
Heterogeneity: Tau2=18.47; Chi2=6.85, df=3(P=0.08); I2=56.22%  
Test for overall effect: Z=0.95(P=0.34)  
Test for subgroup differences: Chi2=5.6, df=1 (P=0.06), I2=64.26%  
Favours probiotic 2010-20 -10 0 Favours control
 
 
Comparison 2.   Probiotic versus lactulose
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 No recovery (incomplete resolution of
clinical symptoms)
3 173 Risk Ratio (M-H, Random, 95%
CI)
1.05 [0.75, 1.47]
1.1 1 month 2 93 Risk Ratio (M-H, Random, 95%
CI)
0.88 [0.53, 1.46]
1.2 3 months 1 80 Risk Ratio (M-H, Random, 95%
CI)
1.24 [0.85, 1.80]
2 Number of adverse events 2 111 Risk Ratio (M-H, Random, 95%
CI)
0.57 [0.06, 5.74]
2.1 1 month 1 31 Risk Ratio (M-H, Random, 95%
CI)
0.19 [0.02, 1.43]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.2 3 months 1 80 Risk Ratio (M-H, Random, 95%
CI)
2.0 [0.19, 21.18]
3 Change of/or withdrawal from treat-
ment
3 190 Risk Ratio (M-H, Random, 95%
CI)
1.10 [0.40, 3.03]
3.1 1 month 2 110 Risk Ratio (M-H, Random, 95%
CI)
0.85 [0.27, 2.64]
3.2 3 months 1 80 Risk Ratio (M-H, Random, 95%
CI)
3.00 [0.33, 27.63]
4 Plasma ammonia concentration
(μmol/L)
2 93 Mean Difference (IV, Random,
95% CI)
-6.61 [-30.05, 16.84]
4.1 1 month 2 93 Mean Difference (IV, Random,
95% CI)
-6.61 [-30.05, 16.84]
5 Change in plasma ammonia concen-
tration (μmol/L)
1 77 Mean Difference (IV, Random,
95% CI)
1.16 [-1.96, 4.28]
6 Plasma ammonia concentration (sub-
group type of probiotic used)
2 93 Mean Difference (IV, Random,
95% CI)
-6.61 [-30.05, 16.84]
6.1 Enterococcus SF68 1 31 Mean Difference (IV, Random,
95% CI)
-17.61 [-26.98, -8.24]
6.2 Mixed 1 62 Mean Difference (IV, Random,
95% CI)
6.40 [-10.10, 22.90]
7 Plasma ammonia concentration (sub-
group grade of hepatic encephalopathy)
2 93 Mean Difference (IV, Random,
95% CI)
-6.61 [-30.05, 16.84]
7.1 Minimal 1 62 Mean Difference (IV, Random,
95% CI)
6.40 [-10.10, 22.90]
7.2 Overt 1 31 Mean Difference (IV, Random,
95% CI)
-17.61 [-26.98, -8.24]
 
 
Analysis 2.1.   Comparison 2 Probiotic versus lactulose, Outcome
1 No recovery (incomplete resolution of clinical symptoms).
Study or subgroup Probiotic Lactulose Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.1.1 1 month  
Loguercio 1987 6/16 9/15 17.26% 0.63[0.29,1.33]
Sharma 2008 15/31 14/31 31.05% 1.07[0.63,1.82]
Subtotal (95% CI) 47 46 48.31% 0.88[0.53,1.46]
Total events: 21 (Probiotic), 23 (Lactulose)  
Heterogeneity: Tau2=0.03; Chi2=1.31, df=1(P=0.25); I2=23.53%  
Favours probiotic 20.5 1.50.7 1 Favours lactulose
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Study or subgroup Probiotic Lactulose Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Test for overall effect: Z=0.5(P=0.62)  
   
2.1.2 3 months  
Mittal 2009 26/40 21/40 51.69% 1.24[0.85,1.8]
Subtotal (95% CI) 40 40 51.69% 1.24[0.85,1.8]
Total events: 26 (Probiotic), 21 (Lactulose)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.12(P=0.26)  
   
Total (95% CI) 87 86 100% 1.05[0.75,1.47]
Total events: 47 (Probiotic), 44 (Lactulose)  
Heterogeneity: Tau2=0.02; Chi2=2.55, df=2(P=0.28); I2=21.68%  
Test for overall effect: Z=0.3(P=0.77)  
Test for subgroup differences: Chi2=1.14, df=1 (P=0.29), I2=12.47%  
Favours probiotic 20.5 1.50.7 1 Favours lactulose
 
 
Analysis 2.2.   Comparison 2 Probiotic versus lactulose, Outcome 2 Number of adverse events.
Study or subgroup Probiotic Lactulose Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.2.1 1 month  
Loguercio 1987 1/16 5/15 53.37% 0.19[0.02,1.43]
Subtotal (95% CI) 16 15 53.37% 0.19[0.02,1.43]
Total events: 1 (Probiotic), 5 (Lactulose)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.62(P=0.11)  
   
2.2.2 3 months  
Mittal 2009 2/40 1/40 46.63% 2[0.19,21.18]
Subtotal (95% CI) 40 40 46.63% 2[0.19,21.18]
Total events: 2 (Probiotic), 1 (Lactulose)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.58(P=0.56)  
   
Total (95% CI) 56 55 100% 0.57[0.06,5.74]
Total events: 3 (Probiotic), 6 (Lactulose)  
Heterogeneity: Tau2=1.55; Chi2=2.23, df=1(P=0.14); I2=55.14%  
Test for overall effect: Z=0.48(P=0.63)  
Test for subgroup differences: Chi2=2.22, df=1 (P=0.14), I2=55.01%  
Favours probiotic 1000.01 100.1 1 Favours lactulose
 
 
Analysis 2.3.   Comparison 2 Probiotic versus lactulose, Outcome 3 Change of/or withdrawal from treatment.
Study or subgroup Probiotic Lactulose Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 1 month  
Loguercio 1987 1/20 2/20 19.04% 0.5[0.05,5.08]
Favours probiotic 1000.01 100.1 1 Favours lactulose
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Study or subgroup Probiotic Lactulose Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Sharma 2008 4/35 4/35 60.19% 1[0.27,3.69]
Subtotal (95% CI) 55 55 79.23% 0.85[0.27,2.64]
Total events: 5 (Probiotic), 6 (Lactulose)  
Heterogeneity: Tau2=0; Chi2=0.26, df=1(P=0.61); I2=0%  
Test for overall effect: Z=0.29(P=0.77)  
   
2.3.2 3 months  
Mittal 2009 3/40 1/40 20.77% 3[0.33,27.63]
Subtotal (95% CI) 40 40 20.77% 3[0.33,27.63]
Total events: 3 (Probiotic), 1 (Lactulose)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.97(P=0.33)  
   
Total (95% CI) 95 95 100% 1.1[0.4,3.03]
Total events: 8 (Probiotic), 7 (Lactulose)  
Heterogeneity: Tau2=0; Chi2=1.25, df=2(P=0.53); I2=0%  
Test for overall effect: Z=0.19(P=0.85)  
Test for subgroup differences: Chi2=0.99, df=1 (P=0.32), I2=0%  
Favours probiotic 1000.01 100.1 1 Favours lactulose
 
 
Analysis 2.4.   Comparison 2 Probiotic versus lactulose, Outcome 4 Plasma ammonia concentration (μmol/L).
Study or subgroup Probiotic Lactulose Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.4.1 1 month  
Sharma 2008 31 75.7 (33) 31 69.3 (33.3) 45.83% 6.4[-10.1,22.9]
Loguercio 1987 16 58.7 (5.9) 15 76.3 (17.6) 54.17% -17.61[-26.98,-8.24]
Subtotal *** 47   46   100% -6.61[-30.05,16.84]
Heterogeneity: Tau2=241.36; Chi2=6.15, df=1(P=0.01); I2=83.74%  
Test for overall effect: Z=0.55(P=0.58)  
   
Total *** 47   46   100% -6.61[-30.05,16.84]
Heterogeneity: Tau2=241.36; Chi2=6.15, df=1(P=0.01); I2=83.74%  
Test for overall effect: Z=0.55(P=0.58)  
Favours probiotic 4020-40 -20 0 Favours lactulose
 
 
Analysis 2.5.   Comparison 2 Probiotic versus lactulose,
Outcome 5 Change in plasma ammonia concentration (μmol/L).
Study or subgroup Probiotic Lactulose Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Mittal 2009 37 -7.3 (7.9) 40 -8.5 (5.8) 100% 1.16[-1.96,4.28]
   
Total *** 37   40   100% 1.16[-1.96,4.28]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.73(P=0.47)  
Favours probiexperimental 52.5-5 -2.5 0 Favours placebocontrol
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Analysis 2.6.   Comparison 2 Probiotic versus lactulose, Outcome 6
Plasma ammonia concentration (subgroup type of probiotic used).
Study or subgroup Probiotic Lactulose Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.6.1 Enterococcus SF68  
Loguercio 1987 16 58.7 (5.9) 15 76.3 (17.6) 54.17% -17.61[-26.98,-8.24]
Subtotal *** 16   15   54.17% -17.61[-26.98,-8.24]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.68(P=0)  
   
2.6.2 Mixed  
Sharma 2008 31 75.7 (33) 31 69.3 (33.3) 45.83% 6.4[-10.1,22.9]
Subtotal *** 31   31   45.83% 6.4[-10.1,22.9]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.76(P=0.45)  
   
Total *** 47   46   100% -6.61[-30.05,16.84]
Heterogeneity: Tau2=241.36; Chi2=6.15, df=1(P=0.01); I2=83.74%  
Test for overall effect: Z=0.55(P=0.58)  
Test for subgroup differences: Chi2=6.15, df=1 (P=0.01), I2=83.74%  
Favours probiotic 4020-40 -20 0 Favours lactulose
 
 
Analysis 2.7.   Comparison 2 Probiotic versus lactulose, Outcome 7 Plasma
ammonia concentration (subgroup grade of hepatic encephalopathy).
Study or subgroup Probiotic Lactulose Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.7.1 Minimal  
Sharma 2008 31 75.7 (33) 31 69.3 (33.3) 45.83% 6.4[-10.1,22.9]
Subtotal *** 31   31   45.83% 6.4[-10.1,22.9]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.76(P=0.45)  
   
2.7.2 Overt  
Loguercio 1987 16 58.7 (5.9) 15 76.3 (17.6) 54.17% -17.61[-26.98,-8.24]
Subtotal *** 16   15   54.17% -17.61[-26.98,-8.24]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.68(P=0)  
   
Total *** 47   46   100% -6.61[-30.05,16.84]
Heterogeneity: Tau2=241.36; Chi2=6.15, df=1(P=0.01); I2=83.74%  
Test for overall effect: Z=0.55(P=0.58)  
Test for subgroup differences: Chi2=6.15, df=1 (P=0.01), I2=83.74%  
Favours probiotic 5025-50 -25 0 Favours lactulose
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Study Probiotics used
Bajaj 2008 Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus, Lactobacillus casei,
and Bifidobacteria.
Liu 2004 Pediacoccus pentoseceus, Leuconostoc mesenteroides, Lactobacillus paracasei, and Lactobacillus
plantarum.
Loguercio 1987 Enterococcus Lactic Acid bacteria strain SF68.
Malaguarnera 2010 Bifidobacterium (subtype not available).
Mittal 2009 VSL#3 (containing Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bi-
fidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei,
Lactobacillus bulgaricus).
Pereg 2011 Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium bifidum, and Streptococcus
thermophiles (Bio-plus, Supherb, Israel).
Sharma 2008 Streptococcus faecalis, Clostridium butyricum, Bacillus mesentricus, and Lactic acid bacillus.
Table 1.   Types of probiotics used across studies 
 
 
A P P E N D I C E S
Appendix 1. Search strategies
 
Database Span of search Search strategy
The Cochrane He-
pato-Biliary Group
Controlled Trials
Register
April 2011. (probiot* OR lactobacil* OR bifidobacter*) AND ('hepatic encephalopath*' OR (liver AND
(diseas* OR cirrhosis*)))
Cochrane Cen-
tral Register of
Controlled Trials
(CENTRAL) in The
Cochrane Library
Issue 1, 2011. #1 LIVER CIRRHOSIS explode all trees (MeSH) 
#2 (liver cirrhosis):ti,ab,kw 
#3 HEPATIC ENCEPHALOPATHY explode all trees (MeSH) 
#4 (hepatic encephalopathy):ti,ab,kw 
#5 (liver next cirrhosis) 
#6 (hepatic next encephalopathy) 
#7 (#1 or #2 or #3 or #4 or #5 or #6) 
#8 probiotics explode all trees (MeSH) 
#9 (probiotics):ti,ab,kw 
#10 lactobacillus explode all trees (MeSH) 
#11 (lactobacillus):ti,kw,ab 
#12 bifidobacterium explode all trees (MeSH) 
#13 (bifidobacterium):ti,kw,ab 
#14 (#8 or #9 or #10 or #11 or #12 or #13) 
#15 (#7 and #14)
MEDLINE (Ovid
SP)
1950 to April 2011. #1 randomised controlled trial.pt. 
#2 controlled clinical trial.pt. 
#3 randomized.ab. 
#4 placebo.ab. 
#5 drug therapy.fs. 
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Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
#6 randomly.ab. 
#7 trial.ab. 
#8 groups.ab. 
#9 or/1-8 
#10 animals.sh. 
#11 9 not 10 
#12 exp hepatic encephalopathy/ 
#13 hepatic encephalopathy.tw 
#14 exp liver cirrhosis/ 
#15 liver cirrhosis.tw 
#16 12 or 13 or 14 or 15 
#17 exp probiotics/ 
#18 probiotic.tw 
#19 exp lactobacillus/ 
#20 lactobacillus.tw 
#21 exp bifidobacterium/ 
#22 bifidobacterium.tw 
#23 17 or 18 or 19 or 20 or 21 or 22 
#24 11 and 16 and 23
EMBASE (OvidSP) 1980 to April 2011. #1 random:.tw. 
#2 clinical trial:.mp. 
#3 exp health care quality/ 
#4 1 or 2 or 3 
#5 exp hepatic encephalopathy/ 
#6 hepatic encephalopathy.tw 
#7 exp liver cirrhosis/ 
#8 liver cirrhosis.tw 
#9 5 or 6 or 7 or 8 
#10 exp probiotics/ 
#11 probiotic.tw 
#12 exp lactobacillus/ 
#13 lactobacillus.tw 
#14 exp bifidobacterium/ 
#15 bifidobacterium.tw 
#16 10 or 11 or 12 or 13 or 14 or 15 
#17 4 and 9 and 16
Science Citation
Index Expanded
(http://apps.isi-
knowledge.com)
1900 to April 2011. #1 Topic=(probiotic OR probiot* OR lactobacil* OR bifidobacter*) 
#2 Topic=(hepatic encephalopath* OR liver diseas*) 
#3 #1 AND #2 
#4 Topic=(random* OR blind* OR placebo*) 
#5 #3 AND #4
  (Continued)
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
The secondary outcome 'improvement: number of participants showing improvement or change in status as defined by each trial' was
dropped from the review as it was not reported in any of the included trials and was felt to be unnecessary because the outcome 'recovery'
conveyed similar information. While we initially planned to assess change in plasma ammonia concentration, this could not be achieved in
all cases due to the presentation of results in articles. Therefore, we created a new outcome 'plasma ammonia concentration'. The time of
day that outcomes were assessed was not reported in any trial and, therefore, not recorded in the review. Although it was not a component
of our protocol, we acknowledge the importance of searching trial registers to locate ongoing and unpublished trials. Therefore, we
searched the WHO international clinical trials registry platform. Details of this search are available under Electronic searches. We did not
conduct fixed-eKect meta-analyses as we anticipated heterogeneity, and hence favoured the more conservative random-eKects model
meta-analysis which allowed for within and amongst trial variability.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Cause of Death;  Gastrointestinal Agents  [*therapeutic use];  Hepatic Encephalopathy  [mortality]  [*therapy];  Lactulose  [*therapeutic
use];  Probiotics  [*therapeutic use];  Quality of Life;  Randomized Controlled Trials as Topic
MeSH check words
Humans
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